[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 798
1. Deschoolmeester V, Baay M, Van Marck E, Weyler J, Vermeulen P, Lardon F, Vermorken JB: Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol; 2010;11:19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients.
  • Colorectal cancer results from the cumulative effect of sequential genetic alterations, leading to the expression of tumor associated antigens possibly inducing a cellular anti-tumor immune response.
  • However, their potential prognostic influence in colorectal cancer remains controversial.
  • Aim of the study was to examine infiltration of CD3+ and CD8+ lymphocytes in colorectal cancer and their prognostic potential.Two-hundred-fifteen colorectal cancer cases, previously analyzed for microsatellite instability (MSI), were selected for immunohistochemical detection of CD3+, CD8+ infiltration and the expression of granzyme B.
  • When samples were analyzed for colon cancer and rectal cancer separately, the results of the overall population were confirmed in colon cancer only.
  • Only early stage and young age (borderline significant for overall population only) were associated with a better overall survival (early disease with disease-free survival also).
  • CONCLUSIONS: In conclusion our results suggest a role for infiltrating CD3+ and CD8+ T lymphocytes in colorectal cancer whereby tumor infiltration could reflect a general principle of antitumor immunity, irrespective of the MSI-status.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Sep;81(2):190-3 [10496341.001]
  • [Cites] Lancet. 2005 Jan 8-14;365(9454):153-65 [15639298.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):609-18 [15659508.001]
  • [Cites] Br J Cancer. 2005 Feb 28;92(4):651-4 [15700032.001]
  • [Cites] Recent Results Cancer Res. 2005;165:260-7 [15865042.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1746-53 [15856045.001]
  • [Cites] Oncol Rep. 2005 Jul;14(1):241-9 [15944796.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):6-10 [16003753.001]
  • [Cites] Eur J Cancer. 2005 Nov;41(17):2645-54 [16239109.001]
  • [Cites] N Engl J Med. 2005 Dec 22;353(25):2640-1 [16371629.001]
  • [Cites] N Engl J Med. 2005 Dec 22;353(25):2654-66 [16371631.001]
  • [Cites] Int J Cancer. 2006 Apr 1;118(7):1721-7 [16231316.001]
  • [Cites] J Clin Lab Anal. 2006;20(2):52-61 [16538640.001]
  • [Cites] Science. 2006 Sep 29;313(5795):1960-4 [17008531.001]
  • [Cites] Aliment Pharmacol Ther. 2006 Oct 15;24(8):1163-77 [17014575.001]
  • [Cites] Ann Surg. 2006 Dec;244(6):986-92; discussion 992-3 [17122624.001]
  • [Cites] Eur J Cancer. 2007 Feb;43(3):624-31 [17223543.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):1883-6 [17332313.001]
  • [Cites] Cancer Immun. 2007;7:7 [17388261.001]
  • [Cites] Eur J Cancer. 2007 Jun;43(9):1348-60 [17512720.001]
  • [Cites] Clin Colorectal Cancer. 2007 Nov;6(10):683-90 [18039421.001]
  • [Cites] Cancer Immunol Immunother. 2008 May;57(5):601-9 [17874100.001]
  • [Cites] J Mol Diagn. 2008 Mar;10(2):154-9 [18258928.001]
  • [Cites] Gastroenterology. 2008 Apr;134(4):988-97 [18395080.001]
  • [Cites] Eur J Cancer. 2008 Oct;44(15):2288-95 [18707864.001]
  • [Cites] Cancer Immun. 2009;9:1 [19226101.001]
  • [Cites] Cancer Res. 2009 Mar 15;69(6):2685-93 [19258510.001]
  • [Cites] Ann Surg. 2009 May;249(5):788-93 [19387324.001]
  • [Cites] Cancer Biother Radiopharm. 2009 Jun;24(3):369-76 [19538060.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Eur J Cancer. 2009 Aug;45(12):2138-45 [19409772.001]
  • [Cites] Fam Cancer. 2009;8(3):231-9 [19165625.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):297-304 [11438476.001]
  • [Cites] Cancer Immunol Immunother. 2002 Jul;51(5):235-47 [12070710.001]
  • [Cites] Oncol Rep. 2003 Mar-Apr;10(2):309-13 [12579264.001]
  • [Cites] Crit Rev Oncol Hematol. 2003 Apr;46(1):33-57 [12672517.001]
  • [Cites] Oncology. 2003;64(3):259-65 [12697967.001]
  • [Cites] Cancer Immunol Immunother. 2003 Jul;52(7):423-8 [12695859.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5564-72 [14500396.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):242-6 [14760116.001]
  • [Cites] Lab Invest. 2004 Apr;84(4):493-501 [14968119.001]
  • [Cites] Br J Surg. 2004 Apr;91(4):469-75 [15048750.001]
  • [Cites] Jpn J Clin Oncol. 2004 Feb;34(2):90-8 [15067103.001]
  • [Cites] J Pathol. 1999 Dec;189(4):487-95 [10629548.001]
  • [Cites] Gut. 2000 Feb;46(2):200-4 [10644313.001]
  • [Cites] Gut. 2001 Mar;48(3):360-6 [11171826.001]
  • [Cites] Int J Cancer. 2001 Jul 1;93(1):6-11 [11391614.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2417-22 [11413533.001]
  • [Cites] Br J Cancer. 2004 Jun 1;90(11):2053-8 [15164120.001]
  • [Cites] Hum Pathol. 2004 Jul;35(7):808-16 [15257543.001]
  • [Cites] Br J Cancer. 2004 Nov 1;91(9):1711-7 [15494715.001]
  • [Cites] Lancet. 1987 Jun 6;1(8545):1303-6 [2884421.001]
  • [Cites] JAMA. 1990 Sep 19;264(11):1444-50 [2202842.001]
  • [Cites] Semin Oncol. 1995 Dec;22(6):600-10 [8539635.001]
  • [Cites] Crit Rev Immunol. 1995;15(3-4):359-84 [8834456.001]
  • [Cites] J Pathol. 1997 Jul;182(3):318-24 [9349235.001]
  • [Cites] Cancer Res. 1998 Aug 15;58(16):3491-4 [9721846.001]
  • [Cites] Am J Pathol. 1998 Oct;153(4):1063-78 [9777938.001]
  • [Cites] Lancet. 1999 Jan 30;353(9150):345-50 [9950438.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1805-13 [10362805.001]
  • [Cites] Hum Pathol. 1999 Jun;30(6):629-34 [10374769.001]
  • [Cites] J Pathol. 1999 May;188(1):14-7 [10398134.001]
  • (PMID = 20385003.001).
  • [ISSN] 1471-2172
  • [Journal-full-title] BMC immunology
  • [ISO-abbreviation] BMC Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2864219
  •  go-up   go-down


2. Li SY, Liang ZJ, Yuan SJ, Yu B, Chen G, Zuo FY, Bai X, Chen G, Wei XJ, Xu YS, Cui W: [Clinical experience of 371 cases of sphincter-preservation with telescopic anastomosis after radical excision for low-middle rectal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi; 2010 Apr;13(4):263-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical experience of 371 cases of sphincter-preservation with telescopic anastomosis after radical excision for low-middle rectal cancer].
  • OBJECTIVE: To evaluate the clinical efficacy, feasibility and safety of sphincter-preservation with telescopic anastomosis of colon and rectal mucosa in low-middle rectal cancer.
  • METHODS: A retrospective analysis was carried out in 371 patients with low-middle rectal cancer in whom telescopic anastomosis was used.
  • The lower margins of the tumors located between 5-8 cm from the anal verge.
  • According to the Duke's stage classification, 120 were TNM stage I, 222 stage II, 26 stage III, and 3 stage IV.
  • CONCLUSION: The sphincter-preservation with telescopic anastomosis procedure is safe and effective for low-middle rectal cancer, and the sphincter function can be well-preserved.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Anastomosis, Surgical / methods. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20422480.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


3. Park IJ, Choi GS, Lim KH, Kang BM, Jun SH: Laparoscopic resection of extraperitoneal rectal cancer: a comparative analysis with open resection. Surg Endosc; 2009 Aug;23(8):1818-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic resection of extraperitoneal rectal cancer: a comparative analysis with open resection.
  • PURPOSE: The aim of this study was to compare the outcomes of laparoscopic surgery with those of open resection in patients with extraperitoneal rectal cancer.
  • METHODS: Five hundred forty-four patients with extraperitoneal rectal cancer who underwent curative resection between 1996 and 2007 were included.
  • Differences were found in preoperative carcinoembryonic antigen (CEA) (LAP group 4.6 ng/ml, OPEN group 7.7 ng/ml, p = 0.001), sphincter preservation (LAP group 82.9%, OPEN group 69.8%, p = 0.001), and mean distance from anal verge (LAP group 4.6 cm, OPEN group 5.2 cm, p = 0.002).
  • Local recurrence and metastasis were similar by stage.
  • CONCLUSIONS: The results of this study show that laparoscopic resection of extraperitoneal rectal cancer was safe and effective.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surg Endosc. 2011 Feb;25(2):658-60 [20632188.001]
  • [CommentIn] Surg Endosc. 2009 Dec;23(12):2871-3 [19688396.001]
  • [Cites] Eur J Surg Oncol. 2002 Mar;28(2):126-34 [11884047.001]
  • [Cites] Br J Surg. 1995 Aug;82(8):1031-3 [7648142.001]
  • [Cites] Surg Endosc. 2004 Oct;18(10):1457-62 [15791369.001]
  • [Cites] Arch Surg. 1998 Aug;133(8):894-9 [9711965.001]
  • [Cites] J Am Coll Surg. 1997 Aug;185(2):105-13 [9249076.001]
  • [Cites] Colorectal Dis. 2006 Jun;8(5):375-88 [16684081.001]
  • [Cites] Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005200 [17054246.001]
  • [Cites] J Am Coll Surg. 1995 Oct;181(4):335-46 [7551328.001]
  • [Cites] Lancet. 1990 May 5;335(8697):1055-9 [1691810.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1718-26 [15894098.001]
  • [Cites] Ann Surg. 2006 Mar;243(3):353-8 [16495700.001]
  • [Cites] Surg Endosc. 2005 Jun;19(6):757-66 [15868256.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):374-9 [11289283.001]
  • [Cites] Br J Surg. 1998 Mar;85(3):355-8 [9529492.001]
  • [Cites] Surg Endosc. 2002 Jan;16(1):7-13 [11961595.001]
  • [Cites] Ann Surg. 2003 Mar;237(3):335-42 [12616116.001]
  • [Cites] Eur J Surg Oncol. 1999 Jun;25(3):284-91 [10336809.001]
  • [Cites] Surgery. 1998 Oct;124(4):612-7; discussion 617-8 [9780979.001]
  • [Cites] Br J Surg. 1996 Aug;83(8):1110 [8869318.001]
  • [Cites] Br J Surg. 2003 Apr;90(4):445-51 [12673746.001]
  • [Cites] Surg Endosc. 2005 Nov;19(11):1468-74 [16222464.001]
  • [Cites] Br J Surg. 1991 Mar;78(3):308-11 [2021845.001]
  • [Cites] Surg Endosc. 2005 Nov;19(11):1460-7 [16206013.001]
  • [Cites] Dis Colon Rectum. 2001 Mar;44(3):315-21 [11289275.001]
  • [Cites] Br J Surg. 1994 Aug;81(8):1224-6 [7953369.001]
  • [Cites] Dis Colon Rectum. 2005 Dec;48(12):2224-31 [16228823.001]
  • [Cites] Ann Surg Oncol. 2006 Mar;13(3):413-24 [16450220.001]
  • [Cites] Surg Endosc. 2004 Feb;18(2):281-9 [14691716.001]
  • (PMID = 19118433.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 1548R74NSZ / Tegafur; 2880D3468G / Levamisole; U3P01618RT / Fluorouracil
  •  go-up   go-down


Advertisement
4. Owen CA, Notingher I, Hill R, Stevens M, Hench LL: Progress in Raman spectroscopy in the fields of tissue engineering, diagnostics and toxicological testing. J Mater Sci Mater Med; 2006 Nov;17(11):1019-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Applications of Raman spectroscopy in cell biology are in the early stages of development, however, recent publications have demonstrated its utilisation as a diagnostic and development tool with the key advantage that investigations of living cells can be performed non-invasively.Some of the research highlighted here demonstrates the ability of Raman spectroscopy to accurately characterise cancer cells and distinguish between similar cell types.
  • The main goals of bio-Raman spectroscopy at this stage are twofold.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Phys Med Biol. 2000 Feb;45(2):R1-59 [10701500.001]
  • [Cites] Int J Cancer. 2003 Dec 20;107(6):1047-52 [14601068.001]
  • [Cites] Nature. 1990 Sep 20;347(6290):301-3 [2205805.001]
  • [Cites] Appl Spectrosc. 2003 Jan;57(1):20A-42A [14610929.001]
  • [Cites] J Cell Biochem. 2006 Sep 1;99(1):178-86 [16598770.001]
  • [Cites] Biopolymers. 2003;72(4):230-40 [12833477.001]
  • [Cites] Biopolymers. 2003;72(1):1-9 [12400086.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92(12):2166-70 [15928665.001]
  • [Cites] Anal Chem. 2004 Jun 1;76(11):3185-93 [15167800.001]
  • [Cites] Exp Cell Res. 1991 Aug;195(2):361-7 [2070819.001]
  • [Cites] IEEE Trans Biomed Eng. 2004 Oct;51(10):1784-93 [15490825.001]
  • [Cites] J Cell Biochem. 2004 Aug 15;92(6):1180-92 [15258901.001]
  • [Cites] J Invest Dermatol. 2004 Feb;122(2):443-9 [15009728.001]
  • [Cites] Biophys J. 2003 Jun;84(6):3968-81 [12770902.001]
  • [Cites] J R Soc Interface. 2004 Nov 22;1(1):79-90 [16849154.001]
  • (PMID = 17122913.001).
  • [ISSN] 0957-4530
  • [Journal-full-title] Journal of materials science. Materials in medicine
  • [ISO-abbreviation] J Mater Sci Mater Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  •  go-up   go-down


5. Balakrishnan K, Verma D, O'Brien S, Kilpatrick JM, Chen Y, Tyler BF, Bickel S, Bantia S, Keating MJ, Kantarjian H, Gandhi V, Ravandi F: Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. Blood; 2010 Aug 12;116(6):886-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six had Rai stage III to IV and were previously heavily treated (median prior therapy = 5).

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2001 Apr 26;165(2):195-200 [11275369.001]
  • [Cites] Blood. 2010 Aug 19;116(7):1083-91 [20442367.001]
  • [Cites] Int Immunopharmacol. 2001 Jun;1(6):1199-210 [11407314.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1755-62 [12685828.001]
  • [Cites] Int Immunopharmacol. 2003 Apr;3(4):541-8 [12689658.001]
  • [Cites] Int Immunopharmacol. 2003 Jun;3(6):879-87 [12781704.001]
  • [Cites] Leukemia. 2004 Mar;18(3):385-93 [14737075.001]
  • [Cites] J Biol Chem. 1969 Feb 25;244(4):644-7 [5768862.001]
  • [Cites] Lancet. 1975 May 3;1(7914):1010-3 [48676.001]
  • [Cites] J Clin Invest. 1980 Jan;65(1):103-8 [6765955.001]
  • [Cites] Cancer Res. 1980 Mar;40(3):588-91 [6937239.001]
  • [Cites] Annu Rev Biochem. 1981;50:845-77 [6267992.001]
  • [Cites] Br J Haematol. 1981 Sep;49(1):23-8 [6974004.001]
  • [Cites] Adv Exp Med Biol. 1986;195 Pt B:191-9 [3094325.001]
  • [Cites] Anal Biochem. 1989 Aug 1;180(2):222-6 [2554751.001]
  • [Cites] Blood. 1996 Jun 15;87(12):4990-7 [8652811.001]
  • [Cites] Biochemistry. 1998 Jun 16;37(24):8615-21 [9628722.001]
  • [Cites] Immunopharmacology. 1998 Jul;40(1):1-9 [9776473.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3607-15 [9817282.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4253-60 [16131572.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2392-8 [16778146.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1098-105 [18309944.001]
  • [Cites] Leuk Res. 2008 Aug;32(8):1268-78 [18279955.001]
  • [Cites] Blood. 2009 Aug 20;114(8):1563-75 [19541822.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4593-8 [11287638.001]
  • (PMID = 20427701.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00289549
  • [Grant] United States / NCI NIH HHS / CA / P01 CA081534; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA81534; United States / PHS HHS / / P30-16672
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Purine Nucleosides; 0 / Pyrimidinones; 426X066ELK / forodesine; EC 2.4.2.1 / Purine-Nucleoside Phosphorylase; EC 3.1.3.2 / Phosphoric Monoester Hydrolases; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  • [Other-IDs] NLM/ PMC2924226
  •  go-up   go-down


6. Andersson KB, Finsen AV, Sjåland C, Winer LH, Sjaastad I, Odegaard A, Louch WE, Wang Y, Chen J, Chien KR, Sejersted OM, Christensen G: Mice carrying a conditional Serca2(flox) allele for the generation of Ca(2+) handling-deficient mouse models. Cell Calcium; 2009 Sep;46(3):219-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In Serca2(flox/flox) Tg(alphaMHC-Cre) embryos with early homozygous cardiac Serca2 disruption, normal embryonic development and yolk sac circulation was maintained up to at least embryonic stage E10.5.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. Marmoset Gene list: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19692123.001).
  • [ISSN] 1532-1991
  • [Journal-full-title] Cell calcium
  • [ISO-abbreviation] Cell Calcium
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL062311; United States / NHLBI NIH HHS / HL / R01 HL108186
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 3.6.3.8 / Sarcoplasmic Reticulum Calcium-Transporting ATPases
  • [Other-IDs] NLM/ NIHMS658853; NLM/ PMC4313567
  •  go-up   go-down


7. Kanoh Y, Ohara T, Egawa S, Baba S, Akahoshi T: Prognostic potential of a PSA complex in sera of prostate cancer patients with alpha2-macroglobulin deficiency. J Clin Lab Anal; 2008;22(4):302-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic potential of a PSA complex in sera of prostate cancer patients with alpha2-macroglobulin deficiency.
  • We previously reported on a number of cases of metastatic prostate cancer (PCa) in which serum alpha2-macroglobulin (alpha2M) levels were markedly decreased to less than 20 mg/dl (alpha2M deficiency).
  • In order to elucidate the relative proportions of free and a prostate-specific antigen (PSA) complex in PCa patients with alpha2M deficiency, we have assessed serum alpha2M and total PSA levels, and ratios of free PSA to total PSA (F/T ratios) at each stage of PCa.


8. Yalman D, Demirci S, Bolukbasi Y, Caliskan C, Ozkok S: Postoperative radiotherapy in rectal cancer: long-term results of 290 patients. Hepatogastroenterology; 2010 Sep-Oct;57(102-103):1099-105
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative radiotherapy in rectal cancer: long-term results of 290 patients.
  • BACKGROUND/AIMS: To evaluate treatment results and to identify prognostic factors affecting local-relapse-free (LRFS), disease-free (DFS) and overall survival (OS) in patients treated with postoperative radiotherapy (RT) for rectal cancer.
  • On multivariate analysis, significant prognostic factors for LRFS were age, pathologic T stage (pT), and distance from anal verge; for DFS were pT stage, and positive surgical margin; for OS were pT and pathologic N (pN) stages.
  • CONCLUSION: Among several prognostic factors, pT stage significantly predicted for LRFS, DFS and OS on multivariate analysis, while pN stage was significant for all three only on univariate analysis.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21410039.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


9. Ohnishi ST, Nishino K, Uchiyama S, Ohnishi T, Yamaguchi M: Ki-energy (life-energy) stimulates osteoblastic cells and inhibits the formation of osteoclast-like cells in bone cell culture models. Evid Based Complement Alternat Med; 2007 Jun;4(2):225-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At the beginning of the second culture stage, Ki was applied once for 10 min.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549240.001).
  • [ISSN] 1741-427X
  • [Journal-full-title] Evidence-based complementary and alternative medicine : eCAM
  • [ISO-abbreviation] Evid Based Complement Alternat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1876607
  •  go-up   go-down


10. Chopra A, Iyer VK, Agarwala S, Mathur SR, Aron M, Gupta SD, Verma K: Apoptotic protein expression, glycogen content, DNA ploidy and cell proliferation in hepatoblastoma subtyping and their role in prognostication. Pediatr Surg Int; 2010 Dec;26(12):1173-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histology typing (p = 0.085), Bcl-xL (p = 0.689), Bax (p = 0.27), CK-19 (p = 0.281), PCNA (p = 0.689), age (p = 0.24), sex (p = 0.5661), stage (p = 0.24) and α-fetoprotein levels (p = 0.49) were unrelated to outcome.


11. Lefevre JH, Parc Y, Kernéis S, Shields C, Touboul E, Chaouat M, Tiret E: Abdomino-perineal resection for anal cancer: impact of a vertical rectus abdominis myocutaneus flap on survival, recurrence, morbidity, and wound healing. Ann Surg; 2009 Nov;250(5):707-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdomino-perineal resection for anal cancer: impact of a vertical rectus abdominis myocutaneus flap on survival, recurrence, morbidity, and wound healing.
  • OBJECTIVES: To evaluate the results of a vertical rectus abdominis myocutaneus (VRAM) flap after abdomino-perineal resection (APR) for anal cancer (AC).
  • The groups (VRAM vs. No VRAM) differed in age at surgery (56.3 vs. 62.1; P = 0.0263); administration of chemotherapy in addition to radiotherapy (81% vs. 59%; P = 0.0218); and stage (ypT3-T4 67.6% vs. 38.4%; P = 0.0394).
  • [MeSH-major] Anus Neoplasms / surgery. Carcinoma, Squamous Cell / surgery. Postoperative Complications. Surgical Flaps. Wound Healing


12. Albright JB, Bonatti H, Stauffer J, Dickson RC, Nguyen J, Harnois D, Jeanpierre C, Hinder R, Steers J, Chua H, Aranda-Michel J: Colorectal and anal neoplasms following liver transplantation. Colorectal Dis; 2010 Jul;12(7):657-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal and anal neoplasms following liver transplantation.
  • OBJECTIVE: Liver transplantation (LT) is the treatment of choice for end-stage liver disease.
  • Data on neoplasms of the colon, rectum and anus in LT are limited.
  • METHOD: A retrospective evaluation of the incidence and clinical course of colorectal and anal malignancies and colonic polyps in a series of 467 consecutive LTs in 402 individuals between 1998 and 2001 was performed.
  • RESULTS: During a median follow up of 5.2 years, three colon adenocarcinomas, one EBV associated cecal posttransplant lymphoproliferative tumour and two HPV associated anal tumours were identified.
  • No patient died from colorectal/anal malignancy.
  • Viral-associated malignancies, including post-transplant lymphoproliferative disorders and anal cancer, are important entities in the LT population suggesting that complete screening of the colon, rectum and anus including pre-LT and post-LT colonoscopy should be utilized.
  • [MeSH-major] Anus Neoplasms / epidemiology. Colonic Neoplasms / epidemiology. Immunosuppression / adverse effects. Liver Transplantation

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19508543.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Stern E, Vacic A, Rajan NK, Criscione JM, Park J, Ilic BR, Mooney DJ, Reed MA, Fahmy TM: Label-free biomarker detection from whole blood. Nat Nanotechnol; 2010 Feb;5(2):138-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This two-stage approach isolates the detector from the complex environment of whole blood, and reduces its minimum required sensitivity by effectively pre-concentrating the biomarkers.
  • We show specific and quantitative detection of two model cancer antigens from a 10 microl sample of whole blood in less than 20 min.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2000 Mar 17;287(5460):1977-8 [10755952.001]
  • [Cites] J Clin Oncol. 2009 Jan 20;27(3):398-403 [19064972.001]
  • [Cites] Nat Biotechnol. 2002 May;20(5):512-5 [11981568.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):243-52 [12671663.001]
  • [Cites] Anal Bioanal Chem. 2003 Oct;377(3):528-39 [12879189.001]
  • [Cites] Nucleic Acids Res. 2004;32(2):535-41 [14744978.001]
  • [Cites] Comb Chem High Throughput Screen. 2004 May;7(3):223-9 [15134528.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7590-4 [7638235.001]
  • [Cites] Int J Biol Markers. 1997 Oct-Dec;12(4):168-73 [9582607.001]
  • [Cites] Clin Chim Acta. 2005 Aug;358(1-2):37-54 [15890325.001]
  • [Cites] Nat Biotechnol. 2005 Oct;23(10):1294-301 [16170313.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 5;103(36):13362-7 [16938886.001]
  • [Cites] J Am Chem Soc. 2006 Dec 20;128(50):16323-31 [17165787.001]
  • [Cites] Nature. 2007 Feb 1;445(7127):519-22 [17268465.001]
  • [Cites] Nature. 2007 Apr 26;446(7139):1066-9 [17460669.001]
  • [Cites] Clin Chim Acta. 2007 May;381(1):93-7 [17382922.001]
  • [Cites] Bioconjug Chem. 2007 May-Jun;18(3):717-23 [17432825.001]
  • [Cites] Nano Lett. 2007 Nov;7(11):3405-9 [17914853.001]
  • [Cites] Nature. 2007 Dec 20;450(7173):1235-9 [18097410.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Nano Lett. 2008 Mar;8(3):945-9 [18266330.001]
  • [Cites] Int J Clin Oncol. 2008 Oct;13(5):447-51 [18946756.001]
  • [Cites] Can J Urol. 2008 Dec;15(6):4363-74 [19046489.001]
  • [Cites] Nat Biotechnol. 2008 Dec;26(12):1373-8 [19029914.001]
  • [Cites] Science. 2001 Aug 17;293(5533):1289-92 [11509722.001]
  • (PMID = 20010825.001).
  • [ISSN] 1748-3395
  • [Journal-full-title] Nature nanotechnology
  • [ISO-abbreviation] Nat Nanotechnol
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB008260; United States / NIBIB NIH HHS / EB / R01 EB008260-03; United States / NIBIB NIH HHS / EB / R01EB008260
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS155229; NLM/ PMC2818341
  •  go-up   go-down


14. Sun W, Fang N, Trewyn BG, Tsunoda M, Slowing II, Lin VS, Yeung ES: Endocytosis of a single mesoporous silica nanoparticle into a human lung cancer cell observed by differential interference contrast microscopy. Anal Bioanal Chem; 2008 Jul;391(6):2119-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocytosis of a single mesoporous silica nanoparticle into a human lung cancer cell observed by differential interference contrast microscopy.
  • In the present work, we demonstrate for the first time that differential interference contrast (DIC) microscopy can be used to observe the entire endocytosis process of MSN into living human lung cancer cells (A549) without fluorescence staining.
  • Finally, by coupling a motorized vertical stage to the DIC microscope, we recorded the location of the MSN in three dimensions.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18488205.001).
  • [ISSN] 1618-2650
  • [Journal-full-title] Analytical and bioanalytical chemistry
  • [ISO-abbreviation] Anal Bioanal Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 7631-86-9 / Silicon Dioxide
  •  go-up   go-down


15. Murph MM, Liu W, Yu S, Lu Y, Hall H, Hennessy BT, Lahad J, Schaner M, Helland A, Kristensen G, Børresen-Dale AL, Mills GB: Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis. PLoS One; 2009;4(5):e5583
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis.
  • Malignant ascites fluid is rich in LPA, and LPA receptors are aberrantly expressed by ovarian cancer cells, implicating LPA in the initiation and progression of ovarian cancer.
  • However, there is an absence of systematic data critically analyzing the transcriptional changes induced by LPA in ovarian cancer.
  • METHODOLOGY AND PRINCIPAL FINDINGS: In this study, gene expression profiling was used to examine LPA-mediated transcription by exogenously adding LPA to human epithelial ovarian cancer cells for 24 h to mimic long-term stimulation in the tumor microenvironment.
  • The resultant transcriptional profile comprised a 39-gene signature that closely correlated to serous epithelial ovarian carcinoma.
  • Hierarchical clustering of ovarian cancer patient specimens demonstrated that the signature is associated with worsened prognosis.
  • They have a higher frequency of stage IIIc serous carcinoma and a greater proportion is deceased.
  • Out of those seven, claudin-1, an adhesion molecule and phenotypic epithelial marker, is the only independent biomarker of serous epithelial ovarian carcinoma.
  • Knockdown of claudin-1 expression in ovarian cancer cells reduces LPA-mediated cellular adhesion, enhances suspended cells and reduces LPA-mediated migration.
  • CONCLUSIONS: The data suggest that transcriptional events mediated by LPA in the tumor microenvironment influence tumor progression through modulation of cell adhesion molecules like claudin-1 and, for the first time, report an LPA-mediated expression signature in ovarian cancer that predicts a worse prognosis.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3704-10 [10589790.001]
  • [Cites] Mol Oncol. 2008 Jun;2(1):54-69 [19081821.001]
  • [Cites] Anal Biochem. 2001 Mar15;290(2):302-13 [11237333.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):291-300 [11330965.001]
  • [Cites] Bioinformatics. 2001 Jun;17(6):520-5 [11395428.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Biochim Biophys Acta. 2002 May 23;1582(1-3):257-64 [12069836.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1073-82 [12615725.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):582-91 [12894246.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Aug;17(4):909-25, vii [12959182.001]
  • [Cites] Genome Biol. 2003;4(10):R70 [14519205.001]
  • [Cites] Nucleic Acids Res. 2003 Dec 15;31(24):e154 [14654707.001]
  • [Cites] Endocrinology. 2004 Jun;145(6):2929-40 [14988385.001]
  • [Cites] J Cell Biochem. 2004 Aug 15;92(6):1115-40 [15258897.001]
  • [Cites] Arterioscler Thromb. 1993 Nov;13(11):1662-7 [8218108.001]
  • [Cites] Biochem J. 1998 Mar 15;330 ( Pt 3):1107-14 [9494074.001]
  • [Cites] Ann Oncol. 1998 Apr;9(4):437-42 [9636836.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):364-8 [9887232.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 25;96(11):6249-54 [10339573.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):355-66 [15864277.001]
  • [Cites] Oncogene. 2005 Jul 7;24(29):4672-87 [15940270.001]
  • [Cites] J Clin Invest. 2005 Jul;115(7):1765-76 [15965503.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9603-6 [16266975.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10602-12 [16288054.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1354-62 [16452189.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2740-8 [16510595.001]
  • [Cites] Matrix Biol. 2006 May;25(4):223-31 [16503403.001]
  • [Cites] J Biol Chem. 2006 Aug 11;281(32):22786-93 [16782709.001]
  • [Cites] Eur J Cancer. 2006 Nov;42(16):2846-54 [16996261.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):591-8 [16797678.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Am J Obstet Gynecol. 2007 Mar;196(3):245.e1-11 [17346539.001]
  • [Cites] Am J Clin Pathol. 2007 Jun;127(6):928-37 [17509990.001]
  • [Cites] Expert Rev Mol Med. 2007;9(28):1-18 [17935635.001]
  • [Cites] Hum Pathol. 2008 May;39(5):747-57 [18439941.001]
  • [Cites] Adv Exp Med Biol. 2008;617:23-40 [18497028.001]
  • [Cites] Clin Cancer Res. 2008 Aug 15;14(16):5198-208 [18698038.001]
  • [Cites] Biochim Biophys Acta. 2008 Sep;1781(9):547-57 [18501205.001]
  • [Cites] J Natl Cancer Inst. 2008 Nov 19;100(22):1630-42 [19001604.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2482-91 [10873103.001]
  • (PMID = 19440550.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA099031; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA098258
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CLDN1 protein, human; 0 / Claudin-1; 0 / Lysophospholipids; 0 / Membrane Proteins; 22002-87-5 / lysophosphatidic acid
  • [Other-IDs] NLM/ PMC2679144
  •  go-up   go-down


16. Griffin JL, Des Rosiers C: Applications of metabolomics and proteomics to the mdx mouse model of Duchenne muscular dystrophy: lessons from downstream of the transcriptome. Genome Med; 2009;1(3):32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • More importantly, they all point to perturbations in proteins, metabolites and metabolic fluxes reflecting mitochondrial energetic alterations, even in the early stage of the dystrophic pathology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5346-50 [1319059.001]
  • [Cites] Science. 1990 Nov 2;250(4981):673-6 [2173137.001]
  • [Cites] J Biol Chem. 1990 Oct 5;265(28):16717-20 [2170350.001]
  • [Cites] Neuromuscul Disord. 1991;1(3):185-94 [1822793.001]
  • [Cites] J Neurol Sci. 1990 Dec;100(1-2):9-13 [2089145.001]
  • [Cites] Prog Clin Biol Res. 1989;306:15-28 [2662210.001]
  • [Cites] Lancet. 1989 Nov 18;2(8673):1211-2 [2478850.001]
  • [Cites] Cell. 1987 Dec 24;51(6):919-28 [3319190.001]
  • [Cites] Nature. 1986 Oct 16-22;323(6089):646-50 [3773991.001]
  • [Cites] Genomics. 1988 Jan;2(1):90-5 [3384440.001]
  • [Cites] Science. 1989 Jun 30;244(4912):1578-80 [2662404.001]
  • [Cites] Nature. 1989 Apr 6;338(6215):509-11 [2648158.001]
  • [Cites] Nature. 1989 Jan 5;337(6202):76-8 [2909892.001]
  • [Cites] Adv Biochem Eng Biotechnol. 2004;91:1-49 [15453191.001]
  • [Cites] Eur J Biochem. 2004 Oct;271(19):3943-52 [15373840.001]
  • [Cites] Metab Eng. 2004 Jan;6(1):44-58 [14734255.001]
  • [Cites] Metab Eng. 2004 Jan;6(1):1-5 [14734250.001]
  • [Cites] Proteomics. 2003 Oct;3(10):1895-903 [14625851.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3556-61 [12893755.001]
  • [Cites] Curr Cancer Drug Targets. 2003 Dec;3(6):445-53 [14683502.001]
  • [Cites] Annu Rev Nutr. 2003;23:379-402 [12704218.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2003 Sep;6(5):511-7 [12913668.001]
  • [Cites] Phytochemistry. 2003 Mar;62(6):929-37 [12590120.001]
  • [Cites] Nature. 2002 Dec 5;420(6915):520-62 [12466850.001]
  • [Cites] FEBS Lett. 2002 Oct 23;530(1-3):109-16 [12387876.001]
  • [Cites] J Cell Biol. 2000 Sep 4;150(5):1209-14 [10974007.001]
  • [Cites] Anal Chem. 2007 Sep 1;79(17):6629-40 [17665876.001]
  • [Cites] Mol Endocrinol. 2007 Sep;21(9):2136-51 [17550978.001]
  • [Cites] J Mol Cell Cardiol. 2007 Aug;43(2):119-29 [17583724.001]
  • [Cites] Anal Biochem. 2007 Aug 1;367(1):28-39 [17560863.001]
  • [Cites] N Engl J Med. 2007 Mar 15;356(11):1140-51 [17360992.001]
  • [Cites] PLoS One. 2006;1:e97 [17183729.001]
  • [Cites] Physiol Genomics. 2006 Oct 11;27(2):178-86 [16868074.001]
  • [Cites] Proteomics. 2006 Aug;6(16):4610-21 [16835851.001]
  • [Cites] Biochim Biophys Acta. 2006 Apr;1764(4):773-85 [16483859.001]
  • [Cites] Cardiovasc Res. 2006 May 1;70(2):354-63 [16466703.001]
  • [Cites] Biochemistry. 2005 Dec 20;44(50):16684-94 [16342958.001]
  • [Cites] J Nutr. 2005 Dec;135(12 Suppl):3027S-3032S [16317166.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):421-32 [16286249.001]
  • [Cites] Biochem Soc Trans. 2005 Dec;33(Pt 6):1413-7 [16246133.001]
  • [Cites] Physiol Rev. 2005 Jul;85(3):1093-129 [15987803.001]
  • [Cites] Muscle Nerve. 2002 Oct;26(4):506-12 [12362416.001]
  • [Cites] Physiol Rev. 2002 Apr;82(2):291-329 [11917091.001]
  • [Cites] Lancet. 2002 Mar 16;359(9310):936-41 [11918913.001]
  • [Cites] Cell. 2002 Jan 11;108(1):5-8 [11792315.001]
  • [Cites] Neuromuscul Disord. 2002 Mar;12(3):247-57 [11801396.001]
  • [Cites] Magn Reson Med. 2001 Aug;46(2):249-55 [11477627.001]
  • [Cites] Neuromuscul Disord. 2001 Jul;11(5):464-9 [11404118.001]
  • [Cites] FASEB J. 2001 Jul;15(9):1655-7 [11427517.001]
  • [Cites] Cardiovasc Res. 2001 Jun;50(3):509-15 [11376626.001]
  • [Cites] Anal Biochem. 2001 Jun 1;293(1):16-21 [11373073.001]
  • [Cites] Neuromuscul Disord. 2001 Apr;11(3):251-9 [11297940.001]
  • [Cites] Nature. 2001 Feb 15;409(6822):860-921 [11237011.001]
  • [Cites] Nat Biotechnol. 2001 Jan;19(1):45-50 [11135551.001]
  • [Cites] Nat Biotechnol. 2000 Nov;18(11):1157-61 [11062433.001]
  • [Cites] FEBS Lett. 2000 Nov 10;484(3):169-74 [11078872.001]
  • [Cites] Nat Biotechnol. 2008 Oct;26(10):1179-86 [18820684.001]
  • [Cites] J Mol Cell Cardiol. 2008 Aug;45(2):230-9 [18590915.001]
  • [Cites] J Biol Chem. 2008 Aug 8;283(32):21978-87 [18544527.001]
  • [Cites] J Biol Chem. 2008 Aug 8;283(32):21988-96 [18544526.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 May 13;105(19):7028-33 [18474859.001]
  • [Cites] J Proteome Res. 2008 May;7(5):2069-77 [18386883.001]
  • [Cites] Nat Protoc. 2007;2(12):3058-62 [18079704.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19345-50 [18032601.001]
  • [Cites] Methods Cell Biol. 2008;84:541-88 [17964943.001]
  • [Cites] Anal Chem. 2007 Oct 1;79(19):7554-9 [17822305.001]
  • [Cites] J Mol Cell Cardiol. 2005 May;38(5):723-33 [15850566.001]
  • [Cites] Trends Biotechnol. 2005 Jan;23(1):28-33 [15629855.001]
  • [Cites] J Biol Chem. 2005 Mar 4;280(9):7530-9 [15546876.001]
  • [Cites] J Neurol Sci. 1998 Oct 8;160(2):148-57 [9849797.001]
  • [Cites] Chem Res Toxicol. 1998 Apr;11(4):260-72 [9548796.001]
  • [Cites] Anat Rec. 1998 Oct;252(2):311-24 [9776086.001]
  • [Cites] Biochem Cell Biol. 1998;76(2-3):532-41 [9923723.001]
  • [Cites] Nat Med. 1999 Mar;5(3):320-6 [10086389.001]
  • [Cites] J Cell Biol. 1999 Mar 22;144(6):1259-70 [10087268.001]
  • [Cites] Nat Med. 1998 Dec;4(12):1441-4 [9846586.001]
  • [Cites] Nat Genet. 1998 May;19(1):79-82 [9590295.001]
  • [Cites] Annu Rev Nutr. 1997;17:559-96 [9240940.001]
  • [Cites] Neuroreport. 1997 Apr 14;8(6):1435-7 [9172149.001]
  • [Cites] Nat Med. 1997 Nov;3(11):1216-21 [9359695.001]
  • [Cites] Nature. 1996 Nov 28;384(6607):349-53 [8934518.001]
  • [Cites] Brain. 1996 Jun;119 ( Pt 3):1039-44 [8673481.001]
  • [Cites] J Mass Spectrom. 1996 Mar;31(3):255-62 [8799277.001]
  • [Cites] Lancet. 1995 May 20;345(8960):1260-4 [7746055.001]
  • [Cites] Cell. 1995 Sep 8;82(5):743-52 [7545544.001]
  • [Cites] J Biol Chem. 1995 Apr 28;270(17):10037-42 [7730305.001]
  • [Cites] J Cell Biol. 1995 Feb;128(3):355-61 [7844149.001]
  • [Cites] Biochem J. 1994 Dec 1;304 ( Pt 2):649-54 [7999003.001]
  • [Cites] J Neurol Sci. 1993 Jun;116(2):201-6 [8393092.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3710-4 [8475120.001]
  • (PMID = 19341503.001).
  • [ISSN] 1756-994X
  • [Journal-full-title] Genome medicine
  • [ISO-abbreviation] Genome Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


17. Park JS, Choi GS, Lim KH, Jang YS, Jun SH: Robotic-assisted versus laparoscopic surgery for low rectal cancer: case-matched analysis of short-term outcomes. Ann Surg Oncol; 2010 Dec;17(12):3195-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robotic-assisted versus laparoscopic surgery for low rectal cancer: case-matched analysis of short-term outcomes.
  • PURPOSE: The aim of this study is to compare short-term outcomes and surgical quality of robot-assisted (RAP) and laparoscopic (LAP) total mesorectal excision (TME) in patients with low rectal cancer.
  • METHODS: From December 2007 to June 2009, 41 consecutive patients with low rectal cancer underwent TME by robot-assisted procedures.
  • The lowest tumor margins were below peritoneal reflection and 1.0-8.0 cm above the anal verge.
  • These patients were matched 1:2 by age, gender, body mass index, date of surgery, American Society of Anesthesiologists score, and tumor stage, with 82 patients who underwent conventional LAP.
  • CONCLUSIONS: RAP was safe and effective for patients with low rectal cancer.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20589436.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Cai W, Chen K, He L, Cao Q, Koong A, Chen X: Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging; 2007 Jun;34(6):850-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Cetuximab, a chimeric monoclonal antibody targeting epidermal growth factor receptor (EGFR) on the surface of cancer cells, was approved by the FDA to treat patients with metastatic colorectal cancer.
  • It is currently also in advanced-stage development for the treatment of several other solid tumors.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Nucl Med Mol Imaging. 2007 Sep;34(9):1510-1 [17447062.001]
  • [Cites] J Nucl Med. 1995 Dec;36(12 ):2363-71 [8523133.001]
  • [Cites] Cell. 2000 Oct 13;103(2):211-25 [11057895.001]
  • [Cites] J Nucl Med. 2005 Nov;46(11):1881-8 [16269603.001]
  • [Cites] Nano Lett. 2006 Apr;6(4):669-76 [16608262.001]
  • [Cites] J Nucl Med. 2005 Nov;46(11):1898-906 [16269605.001]
  • [Cites] J Nucl Med. 2006 Jan;47(1):130-9 [16391197.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jan;6(1):32-43 [15688065.001]
  • [Cites] J Nucl Med. 2006 Jan;47(1):113-21 [16391195.001]
  • [Cites] J Nucl Med. 2003 Oct;44(10 ):1663-70 [14530484.001]
  • [Cites] J Immunol Methods. 1984 Aug 3;72(1):77-89 [6086763.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9673-81 [17018625.001]
  • [Cites] J Nucl Med. 2005 Jan;46 Suppl 1:18S-27S [15653648.001]
  • [Cites] J Nucl Med. 2006 Jul;47(7):1172-80 [16818952.001]
  • [Cites] J Control Release. 2000 Mar 1;65(1-2):271-84 [10699287.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2787-99 [12860957.001]
  • [Cites] J Nucl Med. 2007 Feb;48(2):304-10 [17268029.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2610-6 [15226328.001]
  • [Cites] Nat Biotechnol. 2005 Sep;23 (9):1137-46 [16151407.001]
  • [Cites] Semin Oncol. 2003 Jun;30(3 Suppl 7):3-14 [12840796.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8786-93 [16246975.001]
  • [Cites] Mol Cancer Ther. 2006 Nov;5(11):2624-33 [17121909.001]
  • [Cites] J Nucl Med. 2005 Oct;46(10 ):1707-18 [16204722.001]
  • [Cites] J Natl Cancer Inst. 1996 Dec 4;88(23):1770-6 [8944008.001]
  • [Cites] Eur J Nucl Med. 2001 Sep;28(9):1326-35 [24578054.001]
  • [Cites] J Nucl Med. 2006 Dec;47(12 ):2048-56 [17138749.001]
  • [Cites] Nat Biotechnol. 2005 Sep;23(9):1126-36 [16151406.001]
  • [Cites] Neoplasia. 2005 Mar;7(3):271-9 [15799827.001]
  • [Cites] Ann Pharmacother. 2006 Feb;40(2):241-50 [16403849.001]
  • [Cites] Anal Biochem. 1984 Oct;142(1):68-78 [6440451.001]
  • [Cites] Curr Opin Oncol. 2004 Jul;16(4):385-90 [15187895.001]
  • [Cites] J Nucl Med. 1995 Oct;36(10 ):1818-24 [7562049.001]
  • [Cites] J Nucl Med. 1998 Nov;39(11):1944-51 [9829587.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] J Nucl Med. 2004 Aug;45(8):1390-7 [15299066.001]
  • [Cites] J Nucl Med. 2004 Oct;45(10 ):1683-7 [15471833.001]
  • (PMID = 17262214.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA114747; United States / NCI NIH HHS / CA / R21 CA102123; United States / NIBIB NIH HHS / EB / R21 EB001785; United States / NCI NIH HHS / CA / R24 CA93862; United States / NCI NIH HHS / CA / U54 CA119367
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Copper Radioisotopes; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab
  •  go-up   go-down


19. Skrzydlewska E, Sulkowski S, Koda M, Zalewski B, Kanczuga-Koda L, Sulkowska M: Lipid peroxidation and antioxidant status in colorectal cancer. World J Gastroenterol; 2005 Jan 21;11(3):403-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipid peroxidation and antioxidant status in colorectal cancer.
  • The aim of the present study was to assess the levels of final lipid peroxidation products like malondialdehyde (MDA) and 4-hydroxy-2-nonenal (4-HNE) in primary colorectal cancer.
  • As a control, the same amount of sample was collected from macroscopically unchanged colon regions of the most distant location to the cancer.
  • HPLC revealed levels of vitamins C and E and served as a method to detect terminal products of lipid peroxidation in colorectal cancer.
  • -2.65+/-0.48 nmol/g, Adc.G3-2.15+/-0.44 nmol/g, clinical IV stage 4.04+/-0.47 nmol/g, P<0.001 and 4-HNE-Adc.muc.
  • -0.44+/-0.07 nmol/g, Adc.G3-0.44+/-0.10 nmol/g, clinical IV stage 0.52+/-0.11 nmol/g, P<0.001) as well as increase of Cu,Zn-SOD (Adc.muc.
  • -363+/-72 U/g, Adc.G3-318+/-48 U/g, clinical IV stage 421+/-58 U/g, P<0.001), GSH-Px (Adc.muc.
  • -2143+/-623 U/g, Adc.G3-2005+/-591 U/g, clinical IV stage 2467+/-368 U/g, P<0.001) and GSSG-R (Adc.muc.
  • -880+/-194 U/g, Adc.G3-795+/-228 U/g, clinical IV stage 951+/-243 U/g, P<0.001) in primary tumour comparison with normal colon (MDA-1.39+/-0.15 nmol/g, HNE-0.29+/-0.03 nmol/g, Cu, Zn-SOD-117+/-25 U/g, GSH-Px-1723+/-189 U/g, GSSG-R-625+/-112 U/g) especially in mucinous and G3-grade adenocarcinomas as well as clinical IV stage of colorectal cancer.
  • -40+/-14 U/g, clinical IV stage 33+/-18 U/g vs 84+/-17 U/g, P<0.001) as well as a decreased level of reduced glutathione (clinical IV stage 150+/-48 nmol/g vs 167+/-15 nmol/g, P<0.05) and vitamins C and E (vit.
  • C-clinical IV stage 325+/-92 nmol/g vs 513+/-64 nmol/g, P<0.001; vit.
  • E-clinical IV stage 13.3+/-10.3 nmol/g vs 37.5+/-5.2 nmol/g).
  • CONCLUSION: Colorectal carcinogenesis is associated with serious oxidative stress and confirms that gradual advancement of oxidative-antioxidative disorders is followed by progression of colorectal cancer.


20. Ben-Josef E, Moughan J, Ajani JA, Flam M, Gunderson L, Pollock J, Myerson R, Anne R, Rosenthal SA, Willett C: Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. J Clin Oncol; 2010 Dec 1;28(34):5061-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11.
  • PURPOSE: To determine whether increased duration of radiation therapy (RT) and overall treatment (RX) time has a detrimental effect in anal cancer.
  • Cox proportional hazards models were used with the following variables: RT duration, RT intensity, RX duration, treatment group, age, sex, Karnofsky performance score (KPS), T stage, N stage, and RT dose.
  • Age, sex, KPS, T stage, N stage, and RT dose, but not RT duration, RT intensity, or RX duration, were found to be statistically significant predictors of OS and colostomy-free survival.
  • CONCLUSION: Total treatment time, but not duration of radiation therapy, seems to have a detrimental effect on local failure and colostomy rate in anal cancer.

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 1994 Feb;30(2):109-20 [8184108.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):428-35 [19251377.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Radiother Oncol. 2000 May;55(2):101-10 [10799721.001]
  • [Cites] Radiother Oncol. 2001 May;59(2):187-94 [11325448.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):675-80 [11395235.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):483-93 [11567825.001]
  • [Cites] Lancet Oncol. 2002 Nov;3(11):693-701 [12424072.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):1074-81 [12605987.001]
  • [Cites] Radiother Oncol. 2003 Apr;67(1):69-76 [12758242.001]
  • [Cites] Oncology. 2003;65(1):14-22 [12837978.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1259-73 [12873670.001]
  • [Cites] Eur J Cancer. 1967 Nov;3(4):361-9 [6078936.001]
  • [Cites] Radiat Res. 1969 Feb;37(2):423-34 [5765551.001]
  • [Cites] Br J Radiol. 1973 May;46(545):381-7 [4715162.001]
  • [Cites] Cancer Res. 1976 Oct;36(10):3718-25 [953998.001]
  • [Cites] Br J Cancer. 1977 Sep;36(3):313-21 [921888.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1983 Mar;9(3):321-8 [6841183.001]
  • [Cites] Acta Oncol. 1988;27(2):131-46 [3390344.001]
  • [Cites] Eur J Cancer. 1991;27(5):537-43 [1828958.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1195-202 [1938517.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1529-34 [1938563.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Feb 15;25(3):391-7 [8436516.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Dec 1;27(5):1051-6 [8262826.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):313-24 [9069302.001]
  • [Cites] Cancer. 1997 Jun 15;79(12):2329-35 [9191520.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Oct 1;39(3):651-7 [9336145.001]
  • [Cites] Lancet. 1998 May;351 Suppl 2:SII9-16 [9606361.001]
  • [Cites] Oncology. 1998 Nov-Dec;55(6):525-32 [9778618.001]
  • [Cites] Acta Oncol. 2006;45(6):728-35 [16938816.001]
  • [Cites] Lancet. 2006 Sep 2;368(9538):843-54 [16950362.001]
  • [Cites] JAMA. 2008 Apr 23;299(16):1914-21 [18430910.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):114-8 [18472363.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Oct 15;33(3):549-62 [7558943.001]
  • (PMID = 20956625.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA021661; United States / NCI NIH HHS / CA / U10 CA037422; United States / NCI NIH HHS / CA / U10 CA21661; United States / NCI NIH HHS / CA / U10 CA37422
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC3018356
  •  go-up   go-down


21. Celis JE, Gromova I, Cabezón T, Gromov P, Shen T, Timmermans-Wielenga V, Rank F, Moreira JM: Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease. Mol Oncol; 2007 Dec;1(3):321-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Only one such tumour was found (T71), a CK15-/CK19+/p53+ carcinoma that contained p53 negative non-malignant epithelial cells exhibiting a variety of, CK15/CK19 cellular phenotypes (CK15+/CK19+; CK15+/CK19-; CK15-/CK19+; CK15-/CK19-), often associated with simple columnar cells.
  • Single layers of epithelial cells exhibiting all four CK15/CK19 phenotypes were observed contiguous to areas of atypical ductal hyperplasia that contained p53 positive cells that lost CK15 expression (CK15-/CK19+) and had a very similar phenotype to those of the neighboring ductal carcinoma in situ (DCIS) and invasive cells.
  • The undifferentiated CK15+/CK19+ cells, which had the phenotype CK15+/CK19+/CK14+/CK8+ and -/ER-/PgR-/AR-/CD44+ (weak)/CK17-/p63-/vimentin+/Ki67-/Bcl-2+ (weak)/GATA-3-/p53-, most likely correspond to lineage-restricted luminal progenitor cells able to generate the other more differentiated CK15/CK19 cellular phenotypes, thus giving rise to the daunting intratumour heterogeneity displayed by carcinoma T71.
  • Further molecular characterization of these progenitor cells as well as unraveling of the signaling pathways that regulate their growth and differentiation may prove invaluable for developing novel therapeutic strategies that target cancer at an early stage.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma / genetics. Carcinoma / metabolism. Carcinoma / pathology. Female. Fluorescent Antibody Technique, Direct. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness


22. Staudacher C, Di Palo S, Tamburini AM, Vignali A, Orsenigo E: [The role of neoadjuvant radio-chemotherapy in the treatment of rectal cancer]. Ann Ital Chir; 2007 Nov-Dec;78(6):493-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of neoadjuvant radio-chemotherapy in the treatment of rectal cancer].
  • [Transliterated title] Il ruolo della radiochemioterapia neoadiuvante nel trattamento del tumore del retto.
  • OBJECTIVE: To evaluate oncological and surgical outcome of patients submitted to neoadjuvant therapy for advanced rectal cancer.
  • PATIENTS AND METHOD: One hundred thirty eight patients (86 male, 52 female, mean age 61.4 years), with tumour of lower (58; 42%), middle (66; 48%), upper rectum (14; 10%), showing a clinical stage II (23; 17%) or III (115; 83%) and with an average distance from anal verge of 6.5 cm, submitted to fractionated "long-course" RT with CT locally staged by US and MR before and after neoadjuvant therapy and operated on after 4-6 weeks by its end.
  • Pre-treatment clinical stage was not significant.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18510028.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


23. Vargas C, Martinez A, Kestin LL, Yan D, Grills I, Brabbins DS, Lockman DM, Liang J, Gustafson GS, Chen PY, Vicini FA, Wong JW: Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys; 2005 Aug 1;62(5):1297-308
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.
  • PURPOSE: We analyzed our experience treating localized prostate cancer with image-guided off-line correction with adaptive high-dose radiotherapy (ART) in our Phase II dose escalation study to identify factors predictive of chronic rectal toxicity.
  • MATERIALS AND METHODS: From 1999-2002, 331 patients with clinical stage T1-T3N0M0 prostate cancer were prospectively treated in our Phase II 3D conformal dose escalation ART study to a median dose of 75.6 Gy (range, 63.0-79.2 Gy), minimum dose to confidence limited-planning target volume (cl-PTV) in 1.8 Gy fractions (median isocenter dose = 79.7 Gy).
  • For each case, the rectum (rectal solid) was contoured from the sacroiliac joints or rectosigmoid junction (whichever was higher) to the anal verge or ischial tuberosities (whichever was lower), with a median volume of 81.2 cc.
  • Toxicity was quantified using the National Cancer Institute Common Toxicity Criteria 2.0.
  • Thirty-four patients (crude rate = 10.3%) experienced Grade 2 chronic rectal toxicity at a median interval of 1.1 years.
  • Nine patients (crude rate = 2.7%) experienced Grade > or =3 chronic rectal toxicity (1 was Grade 4) at a median interval of 1.2 years.


24. Adigun AA, Ryde IT, Seidler FJ, Slotkin TA: Organophosphate exposure during a critical developmental stage reprograms adenylyl cyclase signaling in PC12 cells. Brain Res; 2010 May 6;1329:36-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organophosphate exposure during a critical developmental stage reprograms adenylyl cyclase signaling in PC12 cells.
  • These results indicate that OP exposure reprograms the AC pathway during a discrete developmental stage at the commencement of neurodifferentiation, with effects that continue to emerge after OP exposure is discontinued.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHLORPYRIFOS .
  • Hazardous Substances Data Bank. DIAZINON .
  • Hazardous Substances Data Bank. PARATHION .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier B.V. All rights reserved.
  • [Cites] Toxicol Appl Pharmacol. 1998 Jul;151(1):182-91 [9705902.001]
  • [Cites] Chem Res Toxicol. 2004 Aug;17(8):983-98 [15310231.001]
  • [Cites] J Mol Cell Cardiol. 1999 Feb;31(2):413-23 [10093053.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 1999 Apr-Jun;2(2):161-81 [10230392.001]
  • [Cites] Environ Health Perspect. 1999 Feb;107 Suppl 1:71-80 [10229709.001]
  • [Cites] J Pharmacol Exp Ther. 1999 Nov;291(2):503-10 [10525064.001]
  • [Cites] Ann N Y Acad Sci. 2004 Oct;1025:595-601 [15542768.001]
  • [Cites] Brain Res Dev Brain Res. 2005 Feb 8;154(2):239-46 [15707677.001]
  • [Cites] Toxicol Appl Pharmacol. 2005 Mar 1;203(2):154-66 [15710176.001]
  • [Cites] Toxicol Appl Pharmacol. 2005 Aug 1;206(1):17-26 [15963341.001]
  • [Cites] Toxicol Appl Pharmacol. 2005 Sep 1;207(2):112-24 [16102564.001]
  • [Cites] Neurotoxicology. 2005 Aug;26(4):573-87 [16112323.001]
  • [Cites] Environ Health Perspect. 2005 Oct;113(10):1291-4 [16203236.001]
  • [Cites] Toxicology. 2006 Jan 16;217(2-3):221-7 [16289293.001]
  • [Cites] Environ Health Perspect. 2006 Jan;114(1):10-7 [16393651.001]
  • [Cites] Environ Health Perspect. 2006 May;114(5):667-72 [16675418.001]
  • [Cites] Environ Health Perspect. 2006 May;114(5):746-51 [16675431.001]
  • [Cites] Neuropsychopharmacology. 2006 Aug;31(8):1647-58 [16319912.001]
  • [Cites] Environ Health Perspect. 2007 Jan;115(1):93-101 [17366826.001]
  • [Cites] Brain Res Bull. 2007 May 30;72(4-6):232-74 [17452286.001]
  • [Cites] Environ Health Perspect. 2007 Sep;115(9):1306-13 [17805420.001]
  • [Cites] Exp Toxicol Pathol. 2008 Apr;59(6):415-23 [18222074.001]
  • [Cites] Curr Med Chem. 2008;15(22):2230-57 [18781946.001]
  • [Cites] Brain Res Bull. 2010 Jan 15;81(1):85-91 [19615431.001]
  • [Cites] Environ Health Perspect. 2010 Feb;118(2):210-5 [20123610.001]
  • [Cites] Brain Res. 2010 Feb 26;1316:1-16 [20026089.001]
  • [Cites] Dev Biol. 1965 Dec;12(3):451-66 [5884354.001]
  • [Cites] Toxicol Appl Pharmacol. 1999 Nov 1;160(3):217-30 [10544056.001]
  • [Cites] Brain Res. 2000 Feb 28;857(1-2):87-98 [10700556.001]
  • [Cites] Brain Res. 2000 Jun 9;867(1-2):29-39 [10837795.001]
  • [Cites] Brain Res Dev Brain Res. 2000 May 11;121(1):19-27 [10837889.001]
  • [Cites] Anal Biochem. 1985 Oct;150(1):76-85 [3843705.001]
  • [Cites] Environ Health Perspect. 1989 Mar;80:127-42 [2647474.001]
  • [Cites] Fundam Appl Toxicol. 1989 Oct;13(3):484-92 [2612780.001]
  • [Cites] Toxicol Lett. 1994 Jan;70(1):71-6 [8310459.001]
  • [Cites] Toxicology. 1995 Dec 15;104(1-3):129-40 [8560491.001]
  • [Cites] Toxicology. 1996 Aug 1;112(1):57-68 [8792849.001]
  • [Cites] J Mol Cell Cardiol. 1997 Feb;29(2):603-15 [9140819.001]
  • [Cites] Toxicol Appl Pharmacol. 1997 Jul;145(1):158-74 [9221834.001]
  • [Cites] Brain Res. 1997 Sep 26;769(2):211-8 [9374188.001]
  • [Cites] Toxicol Sci. 1998 Jan;41(1):8-20 [9520337.001]
  • [Cites] Brain Res Dev Brain Res. 2000 Jun 30;121(2):189-95 [10876031.001]
  • [Cites] Environ Health Perspect. 2001 Sep;109(9):909-13 [11673119.001]
  • [Cites] Ann N Y Acad Sci. 2002 Jun;965:473-8 [12105122.001]
  • [Cites] Toxicol Appl Pharmacol. 2002 Jul 15;182(2):176-85 [12140181.001]
  • [Cites] Toxicology. 2003 Mar 14;185(1-2):67-78 [12505446.001]
  • [Cites] Brain Res Dev Brain Res. 2003 Dec 30;147(1-2):183-90 [14741763.001]
  • [Cites] Environ Health Perspect. 2004 Feb;112(2):170-8 [14754571.001]
  • [Cites] Environ Health Perspect. 2004 Mar;112(3):295-301 [14998743.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Jul 15;198(2):132-51 [15236950.001]
  • [Cites] Toxicol Lett. 1998 Sep 15;98(3):139-46 [9788582.001]
  • (PMID = 20298678.001).
  • [ISSN] 1872-6240
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES010356-090001; United States / NIEHS NIH HHS / ES / P42 ES010356; United States / NIEHS NIH HHS / ES / ES10356; United States / NIEHS NIH HHS / ES / P42 ES010356-090001
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cholinesterase Inhibitors; 0 / Insecticides; 0 / Organophosphates; 61G466064D / Parathion; EC 4.6.1.1 / Adenylyl Cyclases; JCS58I644W / Chlorpyrifos; YUS1M1Q929 / Diazinon
  • [Other-IDs] NLM/ NIHMS189581; NLM/ PMC2857560
  •  go-up   go-down


25. Nikoleishvili D, Pertia A, Trsintsadze O, Gogokhia N, Managadze L, Chkhotua A: Expression of p27((Kip1)), cyclin D3 and Ki67 in BPH, prostate cancer and hormone-treated prostate cancer cells. Int Urol Nephrol; 2008;40(4):953-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p27((Kip1)), cyclin D3 and Ki67 in BPH, prostate cancer and hormone-treated prostate cancer cells.
  • The goal of the current study was to analyze expression of the markers in benign and malignant prostate cancer tissues.
  • Activity of p27((Kip1)), cyclin D3 and Ki67 was immunohistochemically evaluated in different cells of BPH, prostate cancer (PCa) and hormonally treated prostate cancer (HTPCa) tissues.
  • Intensity of the expression in epithelial, vascular and ductal cells was negatively associated with the tumor stage and Gleason grades.
  • Epithelial and vascular marker expression was positively associated with tumor stage and Gleason grades.
  • Intensity of the markers' expression is associated with tumor stage and grades.


26. Winter L, Bruhn H, Langrehr J, Neuhaus P, Felix R, Hänninen LE: Magnetic resonance imaging in suspected rectal cancer: determining tumor localization, stage, and sphincter-saving resectability at 3-Tesla-sustained high resolution. Acta Radiol; 2007 May;48(4):379-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging in suspected rectal cancer: determining tumor localization, stage, and sphincter-saving resectability at 3-Tesla-sustained high resolution.
  • PURPOSE: To assess image quality and overall accuracy of 3-Tesla (3T)-sustained high-resolution magnetic resonance (MR) imaging for diagnostic preoperative workup in suspected rectal carcinoma.
  • MATERIAL AND METHODS: Twenty-three patients with suspected rectal cancer underwent unenhanced and contrast-enhanced fat-suppressed pelvic high-resolution MR imaging using a four-channel phased-array pelvic coil at 3T.
  • Image quality, tumor stage, distance from the anorectal margin, and sphincter-saving resectability were prospectively assessed by two blinded readers.
  • T stage and N stage were correctly diagnosed in 95% and 91%, respectively.
  • CONCLUSION: MR imaging with phased-array receiver coils at 3T facilitated both visualization of different pathologic conditions of the rectum and accurate determination of tumor stage in rectal carcinomas.
  • Thus, this noninvasive diagnostic approach appeared highly suitable for the assessment of patients with suspected rectal carcinoma.
  • [MeSH-major] Anal Canal / surgery. Image Processing, Computer-Assisted / methods. Magnetic Resonance Imaging / methods. Rectal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17453515.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


27. Manne U, Shanmugam C, Katkoori VR, Bumpers HL, Grizzle WE: Development and progression of colorectal neoplasia. Cancer Biomark; 2010;9(1-6):235-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hence, efforts related to biomarker discovery should focus on identification of individual differences based on tumor stage, tumor anatomic location, and race/ethnicity; on the discovery of molecules (genes, mRNA transcripts, and proteins) relevant to these differences; and on development of therapeutic approaches to target these molecules in developing personalized medicine.
  • [MeSH-minor] Animals. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Carcinoma in Situ / genetics. Carcinoma in Situ / metabolism. Disease Progression. Gene Expression Regulation, Neoplastic. Humans. Prognosis. Risk Factors

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncol Rep. 2004 Aug;12(2):245-51 [15254684.001]
  • [Cites] J Exp Clin Cancer Res. 2006 Sep;25(3):433-42 [17167985.001]
  • [Cites] Biochem Biophys Res Commun. 2007 May 18;356(4):864-71 [17400182.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2006-11 [10473079.001]
  • [Cites] Mutat Res. 1999 Aug;406(2-4):71-7 [10479724.001]
  • [Cites] Cancer Surv. 1995;24:141-55 [7553659.001]
  • [Cites] Pol J Pathol. 2004;55(1):3-12 [15195701.001]
  • [Cites] World J Gastroenterol. 2007 Feb 21;13(7):993-6 [17373731.001]
  • [Cites] Int J Cancer. 2007 Aug 15;121(4):784-90 [17450523.001]
  • [Cites] Leuk Lymphoma. 2001 May;41(5-6):655-8 [11378583.001]
  • [Cites] Gut. 2001 Apr;48(4):526-35 [11247898.001]
  • [Cites] N Engl J Med. 1994 Jul 28;331(4):213-21 [8015568.001]
  • [Cites] Nature. 1997 Sep 18;389(6648):300-5 [9305847.001]
  • [Cites] Science. 1987 Oct 9;238(4824):193-7 [2889267.001]
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5678-82 [10582683.001]
  • [Cites] Carcinogenesis. 1995 Jul;16(7):1461-4 [7614678.001]
  • [Cites] Am J Gastroenterol. 2006 Feb;101(2):385-98 [16454848.001]
  • [Cites] Cell. 1996 Oct 18;87(2):175-85 [8861902.001]
  • [Cites] Eur J Cancer Prev. 1997 Apr;6(2):175-94 [9237069.001]
  • [Cites] Am J Pathol. 2000 Oct;157(4):1105-11 [11021814.001]
  • [Cites] Cancer. 1986 Aug 15;58(4):997-1000 [3719563.001]
  • [Cites] J Histochem Cytochem. 2008 Mar;56(3):305-12 [18071066.001]
  • [Cites] Curr Oncol Rep. 2003 May;5(3):183-91 [12667415.001]
  • [Cites] Virchows Arch. 2007 Apr;450(4):379-85 [17333263.001]
  • [Cites] Int J Biochem Cell Biol. 2008;40(5):874-91 [18280770.001]
  • [Cites] Trends Cell Biol. 2001 Mar;11(3):130-5 [11306274.001]
  • [Cites] Am J Pathol. 1991 Jul;139(1):123-9 [1853928.001]
  • [Cites] JAMA. 2008 Jan 30;299(4):425-36 [18230780.001]
  • [Cites] Cancer Res. 1993 Feb 1;53(3):641-51 [7678777.001]
  • [Cites] Surg Today. 1999;29(7):682-4 [10452254.001]
  • [Cites] Cell. 2009 Dec 24;139(7):1226-8 [20064369.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Oncol Rep. 2002 Nov-Dec;9(6):1189-92 [12375017.001]
  • [Cites] Am J Hum Genet. 1993 Sep;53(3):752-9 [8352280.001]
  • [Cites] Carcinogenesis. 1993 Sep;14(9):1821-4 [8403204.001]
  • [Cites] Cancer. 1977 Nov;40(5 Suppl):2406-13 [922683.001]
  • [Cites] Clin Pharmacokinet. 1989 Apr;16(4):215-37 [2656050.001]
  • [Cites] Br J Cancer. 2000 Feb;82(3):560-7 [10682666.001]
  • [Cites] Science. 1990 Jan 5;247(4938):49-56 [2294591.001]
  • [Cites] Biomark Insights. 2006;2:113-121 [18079988.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23):5628-31 [7585645.001]
  • [Cites] Gastroenterology. 1996 Feb;110(2):375-82 [8566583.001]
  • [Cites] Cancer Lett. 1995 Jun 29;93(1):55-71 [7600544.001]
  • [Cites] Cell Growth Differ. 1996 Jun;7(6):699-710 [8780883.001]
  • [Cites] Anticancer Res. 1999 Jan-Feb;19(1B):727-30 [10216484.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1992;57:345-51 [1339669.001]
  • [Cites] Adv Cancer Res. 2000;77:81-137 [10549356.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1169-74 [8118801.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):3074-8 [15860866.001]
  • [Cites] Gastroenterology. 2009 Jan;136(1):131-7 [19010329.001]
  • [Cites] Br J Cancer. 1998 Jun;77(11):1842-7 [9667656.001]
  • [Cites] Cancer. 1993 Apr 1;71(7):2426-9 [8453566.001]
  • [Cites] Cell. 1996 Oct 18;87(2):197-204 [8861904.001]
  • [Cites] Int J Cancer. 1999 Dec 22;84(6):545-52 [10567896.001]
  • [Cites] Oncology. 2007;72(5-6):397-402 [18196926.001]
  • [Cites] Future Oncol. 2007 Jun;3(3):235-41 [17547516.001]
  • [Cites] Br J Cancer. 1996 Jul;74(2):165-71 [8688317.001]
  • [Cites] Dis Colon Rectum. 1995 Jan;38(1):42-50 [7813344.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1227-34 [9607581.001]
  • [Cites] Cell. 2009 Dec 24;139(7):1315-26 [20064377.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1401-8 [14977843.001]
  • [Cites] Cancer Lett. 2002 Dec 15;188(1-2):231-6 [12406569.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1322-7 [10778957.001]
  • [Cites] Oncology. 1998 Jul-Aug;55(4):307-19 [9663420.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2030-9 [9164215.001]
  • [Cites] Exp Cell Res. 2009 May 1;315(8):1439-47 [19133256.001]
  • [Cites] Lancet Oncol. 2009 Jul;10(7):727-35 [19573802.001]
  • [Cites] Carcinogenesis. 2008 Mar;29(3):579-84 [18192692.001]
  • [Cites] Cancer Biol Ther. 2007 Jul;6(7):1143-7 [17630503.001]
  • [Cites] Cell Cycle. 2009 May 15;8(10):1552-8 [19372761.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Jun;9(6):539-44 [10868685.001]
  • [Cites] Br J Cancer. 1996 Sep;74(5):753-8 [8795578.001]
  • [Cites] Cancer Res. 2008 Jul 15;68(14):5795-802 [18632633.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):754-6 [17228016.001]
  • [Cites] Science. 2008 Sep 5;321(5894):1361-5 [18703712.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):289-95 [9069299.001]
  • [Cites] Expert Rev Anticancer Ther. 2003 Feb;3(1):63-78 [12597351.001]
  • [Cites] Lancet. 2000 Jul 8;356(9224):93-6 [10963244.001]
  • [Cites] Am J Pathol. 1994 Jul;145(1):148-56 [8030745.001]
  • [Cites] Cancer. 1998 Dec 1;83(11):2408-18 [9840542.001]
  • [Cites] Jpn J Cancer Res. 1999 Jul;90(7):711-9 [10470282.001]
  • [Cites] Ann Intern Med. 1995 Mar 1;122(5):321-6 [7847642.001]
  • [Cites] Mol Cell Probes. 1999 Oct;13(5):393-5 [10508562.001]
  • [Cites] Cancer Biomark. 2005;1(4-5):241-50 [17192048.001]
  • [Cites] Jpn J Cancer Res. 1991 Sep;82(9):1003-7 [1682292.001]
  • [Cites] Nat Med. 1997 Feb;3(2):231-4 [9018245.001]
  • [Cites] Cancer. 1994 Mar 1;73(5):1324-31 [7906606.001]
  • [Cites] J Gene Med. 2003 Apr;5(4):287-99 [12692863.001]
  • [Cites] Gut. 1998 May;42(5):673-9 [9659163.001]
  • [Cites] Cell Res. 2008 Oct;18(10):997-1006 [18766170.001]
  • [Cites] Cancer Res. 1991 Mar 1;51(5):1564-7 [1997197.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3706-11 [10097101.001]
  • [Cites] Bioessays. 1995 Jun;17(6):501-8 [7575491.001]
  • [Cites] Br J Cancer. 2001 Mar 2;84(5):651-8 [11237386.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Mol Cell. 2007 Jun 8;26(5):745-52 [17540599.001]
  • [Cites] Arch Pathol Lab Med. 1998 Dec;122(12):1065-76 [9870854.001]
  • [Cites] Nat Genet. 1996 Jan;12(1):97-9 [8528263.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):11-27 [15000146.001]
  • [Cites] Cancer Res. 1996 Jul 15;56(14):3366-70 [8764135.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Int J Cancer. 1997 Jun 20;74(3):346-58 [9221816.001]
  • [Cites] Dig Dis Sci. 2008 Oct;53(10):2723-31 [18299982.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):255-64 [8625232.001]
  • [Cites] Cancer Sci. 2003 Jul;94(7):633-8 [12841874.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1343-9 [11350904.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6416-24 [18676867.001]
  • [Cites] Oncogene. 2007 Jun 28;26(30):4435-41 [17260021.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1067-70 [7576993.001]
  • [Cites] J Pathol. 2004 Apr;202(4):412-20 [15095268.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Jul-Aug;4(5):549-54 [7549813.001]
  • [Cites] Oncogene. 1995 Nov 2;11(9):1675-83 [7478594.001]
  • [Cites] Nat Genet. 2002 Mar;30(3):315-20 [11919562.001]
  • [Cites] Genomics. 1994 Feb;19(3):525-31 [8188295.001]
  • [Cites] Cancer Res. 1993 Sep 1;53(17):4082-8 [7689422.001]
  • [Cites] Nucleic Acids Res. 1991 Sep 11;19(17):4799 [1679931.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):357-65 [12567188.001]
  • [Cites] Int J Cancer. 2009 Jul 1;125(1):171-80 [19350627.001]
  • [Cites] Acta Oncol. 2003;42(4):263-75 [12899497.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4857; author reply 4857-8 [17947740.001]
  • [Cites] Cell. 1993 Nov 19;75(4):817-25 [8242752.001]
  • [Cites] Nucleic Acids Res. 1991 Dec 25;19(24):6969 [1684850.001]
  • [Cites] Int J Cancer. 2000 Sep 20;89(5):423-30 [11008204.001]
  • [Cites] Mol Cell Biol. 1987 Feb;7(2):961-3 [3547088.001]
  • [Cites] Dev Biol. 2006 Sep 1;297(1):14-25 [16872596.001]
  • [Cites] Cancer. 1997 Jul 15;80(2):193-7 [9217029.001]
  • [Cites] Rev Gastroenterol Mex. 1996 Apr-Jun;61(2):100-11 [8927912.001]
  • [Cites] Dis Colon Rectum. 2002 Jan;45(1):127-34; discussion 134-6 [11786778.001]
  • [Cites] Br J Cancer. 2000 May;82(10):1689-93 [10817505.001]
  • [Cites] Nucleic Acids Res. 1991 Dec 25;19(24):6977 [1762941.001]
  • [Cites] Cancer. 1996 Oct 15;78(8):1666-70 [8859178.001]
  • [Cites] N Engl J Med. 2000 Sep 28;343(13):905-14 [11006366.001]
  • [Cites] Front Biosci. 2008;13:1050-61 [17981610.001]
  • [Cites] Cancer J. 2003 Jul-Aug;9(4):302-12 [12967141.001]
  • [Cites] Cancer. 1999 Oct 15;86(8):1421-30 [10526268.001]
  • [Cites] Int J Cancer. 1998 Aug 21;79(4):418-23 [9699536.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1593-611 [11920518.001]
  • [Cites] J Med Genet. 2007 Nov;44(11):702-9 [17873119.001]
  • [Cites] N Engl J Med. 2005 Oct 27;353(17):1793-801 [16251535.001]
  • [Cites] Surg Today. 1995;25(12):1001-7 [8645930.001]
  • [Cites] J Natl Cancer Inst. 1993 Dec 15;85(24):2004-7 [8246286.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1743-52 [15014027.001]
  • [Cites] Cancer Res. 1992 Jul 1;52(13):3801-3 [1319833.001]
  • [Cites] Ann Surg Oncol. 2006 Jun;13(6):887-98 [16614880.001]
  • [Cites] Cancer. 1980 Mar 1;45(5):1029-40 [7020913.001]
  • [Cites] Br J Cancer. 1999 Jan;79(2):191-203 [9888457.001]
  • [Cites] Cell. 1993 Sep 24;74(6):957-67 [8402885.001]
  • [Cites] Cancer Res. 1996 Nov 1;56(21):4862-4 [8895734.001]
  • [Cites] Br J Cancer. 1995 Oct;72(4):981-5 [7547253.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] J Am Coll Surg. 2009 Nov;209(5):645-52 [19854407.001]
  • [Cites] Methods Mol Biol. 2009;472:361-72 [19107442.001]
  • [Cites] Cell. 1991 Aug 9;66(3):601-13 [1678319.001]
  • [Cites] Nature. 1997 Apr 24;386(6627):796-804 [9126737.001]
  • [Cites] J Histochem Cytochem. 2008 Aug;56(8):765-72 [18443365.001]
  • [Cites] J Biol Chem. 1994 Dec 23;269(51):32672-7 [7798274.001]
  • [Cites] Bull Cancer. 2006 Feb 1;93 Suppl 1:S5-9 [16483940.001]
  • [Cites] J Clin Oncol. 2008 Dec 10;26(35):5705-12 [19001320.001]
  • [Cites] Clin Cancer Res. 2009 Apr 1;15(7):2406-16 [19339276.001]
  • [Cites] Hum Pathol. 1995 May;26(5):534-40 [7750937.001]
  • [Cites] Nucleic Acids Res. 1991 Sep 11;19(17):4796 [1716362.001]
  • [Cites] Carcinogenesis. 1996 Feb;17(2):261-4 [8625447.001]
  • [Cites] Science. 1988 Dec 16;242(4885):1528-34 [3201241.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1498-504 [12697873.001]
  • [Cites] Tohoku J Exp Med. 1992 Jul;167(3):243-5 [1488746.001]
  • [Cites] JAMA. 1989 Jun 2;261(21):3099-103 [2654431.001]
  • [Cites] Circ Res. 1996 Feb;78(2):173-9 [8575059.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] Pathol Int. 1994 Jul;44(7):487-504 [7921193.001]
  • [Cites] J Cell Mol Med. 2009 Jan;13(1):39-53 [19175699.001]
  • [Cites] Gastroenterology. 2010 Mar;138(3):969-80.e1-3 [19909744.001]
  • [Cites] Science. 1993 May 7;260(5109):816-9 [8484122.001]
  • [Cites] J Gastroenterol. 2001 Jul;36(7):465-9 [11480790.001]
  • [Cites] J Clin Pathol. 1999 Jun;52(6):455-60 [10562815.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):237-41 [7812951.001]
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4B):2901-7 [16886611.001]
  • [Cites] J Natl Cancer Inst. 2002 Jun 19;94(12):936-42 [12072547.001]
  • [Cites] Gastroenterology. 2004 Apr;126(4):1090-103 [15057748.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5096-104 [15958553.001]
  • [Cites] Cell. 1993 Jun 18;73(6):1059-65 [8513492.001]
  • [Cites] Cell. 1992 Nov 13;71(4):587-97 [1423616.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4017-25 [11051251.001]
  • [Cites] Oncogene. 1999 Jun 10;18(23):3471-80 [10376525.001]
  • [Cites] Pathobiology. 1997;65(3):140-5 [9309780.001]
  • [Cites] J Clin Gastroenterol. 1992 Dec;15(4):317-20 [1294637.001]
  • [Cites] Br J Cancer. 1997;75(3):427-31 [9020491.001]
  • [Cites] Dis Colon Rectum. 1997 Jul;40(7):785-90 [9221853.001]
  • [Cites] J Cell Physiol. 1995 Nov;165(2):239-45 [7593201.001]
  • [Cites] Curr Oncol Rep. 2005 May;7(3):181-5 [15847708.001]
  • [Cites] Gastroenterology. 1999 Aug;117(2):350-8 [10419916.001]
  • [Cites] Mol Cell Biol. 2008 Sep;28(17):5369-80 [18591254.001]
  • [Cites] Oncogene. 1995 Apr 20;10(8):1581-6 [7731713.001]
  • [Cites] J Biol Chem. 1994 Nov 18;269(46):28764-8 [7961830.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Sep 12;374(1):164-8 [18625198.001]
  • [Cites] Gut. 2008 May;57(5):623-7 [18178612.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] J Natl Cancer Inst. 2009 Oct 7;101(19):1308-24 [19738166.001]
  • [Cites] Cell Prolif. 2000 Oct;33(5):301-6 [11063132.001]
  • [Cites] Pathol Oncol Res. 2004;10(2):74-9 [15188022.001]
  • [Cites] Cancer. 2004 Jul 1;101(1):66-76 [15221990.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):207-11 [17044027.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 1;140(1):23-30 [12550754.001]
  • [Cites] Cancer. 2003 Jan 15;97(2):517-24 [12518377.001]
  • [Cites] Br J Cancer. 1994 Jun;69(6):979-85 [8198989.001]
  • [Cites] Cancer Cell. 2007 Nov;12(5):414-8 [17996645.001]
  • [Cites] Breast Dis. 2008;29:27-36 [19029622.001]
  • [Cites] EMBO J. 1991 Oct;10(10):2821-32 [1833184.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2803-7 [10914727.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Oct 1;18(7):683-92 [14510741.001]
  • [Cites] J Clin Lab Anal. 1999;13(6):291-5 [10633297.001]
  • [Cites] Am J Pathol. 1993 Jun;142(6):1695-700 [8506941.001]
  • [Cites] Science. 1991 Mar 15;251(4999):1366-70 [1848370.001]
  • [Cites] Nature. 1993 Dec 16;366(6456):701-4 [8259214.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):767-72 [17228023.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] JAMA. 2005 Oct 5;294(13):1634-46 [16204663.001]
  • [Cites] Int J Cancer. 1993 Feb 1;53(3):382-7 [8094072.001]
  • [Cites] Biotech Histochem. 2009 Apr;84(2):39-45 [19212825.001]
  • [Cites] Science. 1991 Aug 9;253(5020):665-9 [1651563.001]
  • [Cites] J Cancer Res Clin Oncol. 1996;122(2):122-6 [8576279.001]
  • [Cites] Br J Surg. 2002 Aug;89(8):1008-13 [12153626.001]
  • [Cites] Int J Cancer. 2005 Oct 10;116(6):914-9 [15856472.001]
  • [Cites] Int J Cancer. 2002 Feb 1;97(4):403-9 [11802199.001]
  • [Cites] Cancer. 1993 Nov 15;72(10):3131-5 [8221580.001]
  • [Cites] Cell. 1996 Jun 28;85(7):947-50 [8674122.001]
  • [Cites] Cancer Res. 1992 May 1;52(9):2616-9 [1314700.001]
  • [Cites] Scand J Gastroenterol. 1987 Sep;22(7):833-41 [3672041.001]
  • [Cites] Oncology. 2000;58(1):45-51 [10644940.001]
  • [Cites] Mol Nutr Food Res. 2005 Jun;49(6):609-19 [15864790.001]
  • [Cites] Breast Cancer Res Treat. 2004 Sep;87(2):197-201 [15377844.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1149-58 [9515799.001]
  • [Cites] Cancer Biomark. 2010;9(1-6):21-39 [22112468.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):5849-52 [8261392.001]
  • [Cites] Am J Gastroenterol. 1995 Mar;90(3):353-65 [7872270.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5C):3907-12 [11268475.001]
  • [Cites] Nat Genet. 2006 Sep;38(9):1060-5 [16878133.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2371-6 [9796967.001]
  • [Cites] Apoptosis. 2009 Apr;14(4):584-96 [19156528.001]
  • [Cites] Cancer. 1996 Apr 15;77(8 Suppl):1729-35 [8608570.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):615-22 [12894249.001]
  • [Cites] Br J Cancer. 2010 Jan 5;102(1):151-61 [19935791.001]
  • [Cites] Int J Cancer. 1998 Aug 21;79(4):390-5 [9699532.001]
  • [Cites] Cancer. 2010 Aug 1;116(15):3577-86 [20564074.001]
  • [Cites] Cancer Res. 1989 Aug 15;49(16):4402-6 [2568169.001]
  • [Cites] Cancer Biomark. 2007;3(6):301-13 [18048968.001]
  • [Cites] Gene. 1988 Oct 30;70(2):245-52 [2905688.001]
  • [Cites] Nat Genet. 2001 Oct;29(2):117-29 [11586292.001]
  • [Cites] Acta Pharmacol Sin. 2009 Nov;30(11):1537-42 [19820721.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):792-801 [12576452.001]
  • [Cites] Am J Clin Nutr. 1978 Oct;31(10 Suppl):S216-S220 [707376.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Nov;47(11):939-46 [18663744.001]
  • [Cites] Oncol Rep. 1999 May-Jun;6(3):597-9 [10203598.001]
  • [Cites] Oncogene. 1999 May 20;18(20):3098-103 [10340381.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Dec;31(4):959-70 [12489272.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):60-5 [12506171.001]
  • [Cites] Genes Chromosomes Cancer. 2010 Mar;49(3):270-81 [19998449.001]
  • [Cites] Int J Cancer. 2000 Nov 1;88(3):479-85 [11054680.001]
  • [Cites] Oncogene. 2009 Mar 12;28(10):1385-92 [19137007.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2345-9 [9122197.001]
  • [Cites] Diagn Mol Pathol. 1995 Mar;4(1):54-8 [7735557.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Jul;2(7):364-9 [16075796.001]
  • [Cites] Oncogene. 1991 Sep;6(9):1691-2 [1923533.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5187-90 [7585571.001]
  • [Cites] EMBO J. 2000 Apr 17;19(8):1745-54 [10775259.001]
  • [Cites] Cancer. 1997 Jan 15;79(2):233-44 [9010096.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1831-6 [11078760.001]
  • [Cites] Nat Genet. 1994 Mar;6(3):273-81 [8012390.001]
  • [Cites] Annu Rev Genet. 1992;26:507-26 [1482123.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1364-74 [10334520.001]
  • [Cites] Science. 1996 Jan 19;271(5247):350-3 [8553070.001]
  • [Cites] Cell. 1996 Oct 18;87(2):187-95 [8861903.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2456-67 [9874449.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1112-7 [12631615.001]
  • [Cites] Oncogene. 2008 Apr 3;27(15):2128-36 [17968323.001]
  • [Cites] J Immunother. 2001 Mar-Apr;24(2):172-83 [11265775.001]
  • [Cites] Genes Dev. 2007 Oct 15;21(20):2525-38 [17938238.001]
  • [Cites] Oncogene. 1993 Jun;8(6):1703-5 [8502490.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2606-11 [15814640.001]
  • [Cites] Genes Dev. 2007 Jul 15;21(14):1817-31 [17639085.001]
  • [Cites] J Biol Chem. 1996 Dec 13;271(50):31775-8 [8943213.001]
  • [Cites] Int J Cancer. 2000 Jan 20;89(1):14-8 [10719725.001]
  • [Cites] Lancet. 2000 Mar 25;355(9209):1041-7 [10744089.001]
  • [Cites] Expert Rev Anticancer Ther. 2003 Jun;3(3):367-80 [12820779.001]
  • [Cites] Int J Oncol. 1999 Jul;15(1):53-8 [10375593.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3819-26 [8508350.001]
  • [Cites] Cancer Genomics Proteomics. 2006 Oct;3(5):317-324 [18172508.001]
  • [Cites] Gastroenterology. 2007 Dec;133(6):1840-8 [17967459.001]
  • [Cites] Oncogene. 1994 Nov;9(11):3227-31 [7936646.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3495-503 [11705868.001]
  • [Cites] Med Oncol. 2010 Dec;27(4):1324-8 [20012233.001]
  • [Cites] J Clin Gastroenterol. 1996 Sep;23(2):105-8 [8877635.001]
  • [Cites] Curr Treat Options Oncol. 2003 Oct;4(5):393-403 [12941199.001]
  • [Cites] Res Commun Mol Pathol Pharmacol. 2001 Jul;109(1-2):25-34 [11458982.001]
  • [Cites] Cancer Res. 1993 Jun 15;53(12):2723-7 [8504411.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2563-9 [12171884.001]
  • [Cites] Cancer. 1996 Dec 15;78(12):2478-84 [8952554.001]
  • [Cites] Lancet. 1989 Aug 12;2(8659):353-6 [2569552.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1277-84 [10545994.001]
  • [Cites] Cancer Res. 2009 Jan 15;69(2):678-86 [19147584.001]
  • [Cites] Semin Oncol. 2001 Feb;28(1 Suppl 1):14-9 [11273584.001]
  • [Cites] Anticancer Res. 2006 Jan-Feb;26(1B):507-10 [16739311.001]
  • [Cites] Oncol Rep. 2009 Mar;21(3):761-7 [19212637.001]
  • [Cites] Hum Pathol. 2010 Jun;41(6):867-76 [20129645.001]
  • [Cites] Oncogene. 2008 Oct 9;27(46):6044-55 [18591935.001]
  • [Cites] Virchows Arch. 2009 Apr;454(4):359-67 [19288129.001]
  • [Cites] Curr Opin Oncol. 2001 May;13(3):168-75 [11307060.001]
  • [Cites] Cell. 1993 Nov 19;75(4):805-16 [8242751.001]
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1155-61 [19190129.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4577-82 [12907634.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):896-902 [11550163.001]
  • [Cites] World J Surg. 1997 Sep;21(7):715-20 [9276702.001]
  • [Cites] Mol Cell Biol. 2000 Feb;20(3):1044-54 [10629061.001]
  • [Cites] Gastroenterology. 2007 Dec;133(6):1849-57 [18054557.001]
  • [Cites] J Biol Chem. 1997 Nov 21;272(47):29407-10 [9367993.001]
  • [Cites] Science. 1992 May 8;256(5058):827-30 [1589764.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3631-52 [10550163.001]
  • [Cites] Nature. 1988 Jan 21;331(6153):273-7 [2827040.001]
  • [Cites] Gene. 2008 May 15;414(1-2):95-105 [18372118.001]
  • [Cites] Nat Med. 1996 Jun;2(6):676-81 [8640559.001]
  • [Cites] Dis Colon Rectum. 1998 Oct;41(10):1262-72 [9788390.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1279-83 [19190326.001]
  • [Cites] Br J Cancer. 1991 Feb;63(2):317-9 [1997114.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Apr;5(4):285-91 [8722220.001]
  • [Cites] Nat Genet. 1997 Apr;15 Spec No:417-74 [9140409.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2640-7 [7989939.001]
  • [Cites] Br J Cancer. 1996 Aug;74(3):342-51 [8695347.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1204-13 [11350885.001]
  • [Cites] Clin Cancer Res. 1995 Oct;1(10):1103-10 [9815900.001]
  • [Cites] Oncogene. 1994 Nov;9(11):3367-70 [7936663.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Dec;130(12):728-32 [15365822.001]
  • [Cites] Eur J Cancer. 1997 Feb;33(2):214-9 [9135491.001]
  • [Cites] Gut. 1998 Sep;43(3):383-7 [9863484.001]
  • [Cites] Cell. 1993 Aug 27;74(4):609-19 [8358790.001]
  • [Cites] Arch Pathol Lab Med. 2001 Jan;125(1):91-8 [11151060.001]
  • [Cites] Clin Cancer Res. 2008 Oct 1;14(19):5939-40 [18829469.001]
  • [Cites] Gut. 2002 Apr;50(4):520-4 [11889073.001]
  • [Cites] Cell. 1996 Aug 23;86(4):543-52 [8752209.001]
  • [Cites] Cancer Lett. 1987 Oct 30;37(2):147-51 [3677050.001]
  • [Cites] Cell. 1998 Mar 6;92(5):645-56 [9506519.001]
  • [Cites] Lancet. 2000 May 20;355(9217):1745-50 [10832824.001]
  • [Cites] Immunol Res. 1998;17(3):313-27 [9638475.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):84-9 [12909219.001]
  • [Cites] J Biochem Mol Biol. 2003 Jul 31;36(4):354-8 [12895292.001]
  • [Cites] Ann N Y Acad Sci. 1992 Nov 21;663:139-53 [1482047.001]
  • [Cites] N Engl J Med. 2001 Apr 19;344(16):1196-206 [11309634.001]
  • [Cites] Science. 2000 Nov 3;290(5493):989-92 [11062132.001]
  • [Cites] Tumour Biol. 2008;29(1):28-34 [18497546.001]
  • [Cites] Carcinogenesis. 1995 Jul;16(7):1655-7 [7614702.001]
  • [Cites] Carcinogenesis. 2008 Jul;29(7):1306-11 [18477647.001]
  • [Cites] Dtsch Arztebl Int. 2009 Mar;106(12):202-6 [19471640.001]
  • [Cites] Eur J Cancer. 1996 Oct;32A(11):1963-7 [8943682.001]
  • (PMID = 22112479.001).
  • [ISSN] 1875-8592
  • [Journal-full-title] Cancer biomarkers : section A of Disease markers
  • [ISO-abbreviation] Cancer Biomark
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U24CA086359-10; United States / NCI NIH HHS / CA / 2R01-CA98932; United States / NCI NIH HHS / CA / U54 CA118623; United States / NCI NIH HHS / CA / U54 CA118948; United States / NCI NIH HHS / CA / R01 CA098932; United States / NCI NIH HHS / CA / R03-CA139629-01; United States / NCI NIH HHS / CA / R03 CA139629; United States / NCI NIH HHS / CA / U24 CA086359; United States / NCI NIH HHS / CA / U54CA118948
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS402043; NLM/ PMC3445039
  •  go-up   go-down


28. Wang Y, Romigh T, He X, Orloff MS, Silverman RH, Heston WD, Eng C: Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines. Hum Mol Genet; 2010 Nov 15;19(22):4319-29
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines.
  • Decreased PTEN expression is correlated with prostate cancer progression.
  • Over-expression of AR and upregulation of AR transcriptional activity are often observed in the later stages of prostate cancer.
  • Furthermore, resveratrol, a phytoalexin enriched in red grapes, strawberries and peanuts, has been shown to inhibit AR transcriptional activity in prostate cancer cells.
  • In this study, we use prostate cancer cell lines to test the hypothesis that resveratrol inhibits cellular proliferation in both AR-dependent and -independent mechanisms.
  • We show that resveratrol inhibits AR transcriptional activity in both androgen-dependent and -independent prostate cancer cells.
  • Thus, resveratrol may act as potential adjunctive treatment for late-stage hormone refractory prostate cancer.


29. Karitskaya I, Aksenov N, Vassilieva I, Zenin V, Marakhova I: Long-term regulation of Na,K-ATPase pump during T-cell proliferation. Pflugers Arch; 2010 Sep;460(4):777-89
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our data demonstrate that in mitogen-stimulated human blood lymphocytes, enhanced ouabain-sensitive Rb(K) fluxes in the middle/late stage of G(0)/G(1)/S transit are associated with the increased number of Na,K-ATPase pumps expressed at the cell surface (as determined by the [(3)H]ouabain binding).
  • The elevated K transport as well as the increased expression of Na,K-ATPase is closely associated with the IL-2-dependent stage of T-cell response.
  • It is concluded that during the lymphocyte transition from resting stage to proliferation, (1) long-term activation of Na,K-ATPase pump is due to the enhanced expression of Na,K-ATPase protein and mRNA, and (2) the cytokine signaling via the IL-2 receptor is necessary for the cell cycle-associated upregulation of Na,K-ATPase.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Biochem. 2002 May;269(10):2424-33 [12027879.001]
  • [Cites] FEBS Lett. 2005 May 23;579(13):2773-80 [15907480.001]
  • [Cites] Physiol Rev. 1989 Apr;69(2):417-81 [2648419.001]
  • [Cites] J Immunol. 1999 Apr 1;162(7):3897-904 [10201908.001]
  • [Cites] Gen Physiol Biophys. 1989 Jun;8(3):273-82 [2548916.001]
  • [Cites] Annu Rev Immunol. 1997;15:707-47 [9143705.001]
  • [Cites] J Cell Biol. 1992 Mar;116(5):1071-80 [1740466.001]
  • [Cites] Crit Rev Immunol. 1997;17(2):155-78 [9094451.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] FEBS Lett. 1991 Sep 2;289(1):8-10 [1654277.001]
  • [Cites] J Cell Physiol. 1995 Nov;165(2):246-53 [7593202.001]
  • [Cites] Cytokine Growth Factor Rev. 1997 Dec;8(4):313-32 [9620644.001]
  • [Cites] Annu Rev Physiol. 2002;64:1-18 [11826261.001]
  • [Cites] Immunity. 1999 Aug;11(2):225-30 [10485657.001]
  • [Cites] Annu Rev Physiol. 1978;40:19-41 [147644.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 27;94(11):5943-8 [9159180.001]
  • [Cites] Science. 1986 Oct 10;234(4773):161-6 [3018928.001]
  • [Cites] FEBS Lett. 1986 Oct 6;206(2):199-202 [3019770.001]
  • [Cites] Biochem Cell Biol. 1987 Feb;65(2):95-104 [3030372.001]
  • [Cites] Cell. 1999 Mar 5;96(5):611-4 [10089876.001]
  • [Cites] J Biol Chem. 2000 Jan 21;275(3):1976-86 [10636900.001]
  • [Cites] Soc Gen Physiol Ser. 1985;39:193-204 [2984780.001]
  • [Cites] Clin Cancer Res. 1999 Jun;5(6):1569-82 [10389946.001]
  • [Cites] Biochim Biophys Acta. 1998 Jan 5;1368(1):61-72 [9459585.001]
  • [Cites] J Physiol. 1972 Jul;224(2):441-62 [4262774.001]
  • [Cites] FEBS Lett. 1999 Aug 6;456(2):285-9 [10456325.001]
  • [Cites] Cell Physiol Biochem. 2001;11(1):19-26 [11275679.001]
  • [Cites] Am J Physiol Cell Physiol. 2000 Sep;279(3):C541-66 [10942705.001]
  • [Cites] J Exp Biol. 1986 Sep;124:359-73 [2428906.001]
  • [Cites] J Cell Biol. 2000 Sep 18;150(6):1435-44 [10995447.001]
  • [Cites] Int J Hematol. 2001 Apr;73(3):271-7 [11345192.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Arch Biochem Biophys. 1987 Feb 1;252(2):515-25 [3028270.001]
  • [Cites] J Cell Physiol. 1988 Nov;137(2):329-36 [3263971.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):37137-49 [10961988.001]
  • [Cites] Immunobiology. 1986 Jul;171(4-5):436-50 [3091487.001]
  • (PMID = 20461527.001).
  • [ISSN] 1432-2013
  • [Journal-full-title] Pflugers Archiv : European journal of physiology
  • [ISO-abbreviation] Pflugers Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Interleukin-2; EC 3.6.3.9 / Sodium-Potassium-Exchanging ATPase
  •  go-up   go-down


30. Lipkus IM, Peters E, Kimmick G, Liotcheva V, Marcom P: Breast cancer patients' treatment expectations after exposure to the decision aid program adjuvant online: the influence of numeracy. Med Decis Making; 2010 Jul-Aug;30(4):464-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer patients' treatment expectations after exposure to the decision aid program adjuvant online: the influence of numeracy.
  • for short) helps breast cancer patients make treatment decisions by providing numerical estimates of treatment efficacy (e.g., 10-y relapse or survival).
  • Pooling across 2 studies totaling 105 women with estrogen receptor-positive, early-stage breast cancer, the authors explored patients' treatment expectations, perceived benefit from treatments, and confidence of personal benefit from treatments.
  • Patients who were more numerate were more likely to provide estimates of cancer-free survival that matched the estimates provided by Adjuvant!
  • for each treatment option compared with patients with lower numeracy (odds ratios of 1.6 to 2.4).
  • increased, so did patients' estimates of cancer-free survival (0.37 > r(s) > 0.48) and their perceptions of treatment benefit from hormonal therapy (r(s) = 0.28) and combined therapy (r(s) = 0.27).

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Decis Making. 2001 Jan-Feb;21(1):37-44 [11206945.001]
  • [Cites] Risk Anal. 2009 Oct;29(10):1473-88 [19671102.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):980-91 [11181660.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 16;95(8):581-7 [12697850.001]
  • [Cites] Patient Educ Couns. 1999 Jul;37(3):283-91 [14528554.001]
  • [Cites] Cancer. 1984 Jun 15;53(12):2736-40 [6326993.001]
  • [Cites] Br J Cancer. 1988 Sep;58(3):355-8 [2460120.001]
  • [Cites] J Clin Oncol. 1989 Sep;7(9):1192-200 [2671280.001]
  • [Cites] Ann Intern Med. 1992 Jul 1;117(1):53-8 [1596048.001]
  • [Cites] Eff Clin Pract. 1999 Jul-Aug;2(4):176-83 [10539543.001]
  • [Cites] BMC Med Inform Decis Mak. 2004 Nov 16;4:20 [15546488.001]
  • [Cites] Breast Cancer. 2005;12(1):39-44 [15657522.001]
  • [Cites] Med Decis Making. 2005 May-Jun;25(3):301-7 [15951457.001]
  • [Cites] Psychooncology. 2005 Aug;14(8):647-60 [15580617.001]
  • [Cites] J Natl Cancer Inst. 2006 Sep 6;98(17):1183-92 [16954471.001]
  • [Cites] Psychooncology. 2006 Nov;15(11):1001-13 [16511899.001]
  • [Cites] Med Care Res Rev. 2007 Apr;64(2):169-90 [17406019.001]
  • [Cites] Health Aff (Millwood). 2007 May-Jun;26(3):741-8 [17485752.001]
  • [Cites] Med Decis Making. 2007 Sep-Oct;27(5):672-80 [17641137.001]
  • [Cites] Med Decis Making. 2007 Sep-Oct;27(5):696-713 [17873259.001]
  • [Cites] Cancer. 2008 Dec 15;113(12):3382-90 [19012353.001]
  • [Cites] Health Psychol. 2009 Mar;28(2):210-6 [19290713.001]
  • [Cites] J Cancer Educ. 2009;24(3):194-9 [19526406.001]
  • [Cites] J Exp Psychol Appl. 2009 Sep;15(3):213-27 [19751072.001]
  • [CommentIn] Med Decis Making. 2010 Jul-Aug;30(4):422-3 [20634546.001]
  • (PMID = 20160070.001).
  • [ISSN] 1552-681X
  • [Journal-full-title] Medical decision making : an international journal of the Society for Medical Decision Making
  • [ISO-abbreviation] Med Decis Making
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA068438; United States / NCI NIH HHS / CA / 5 P50 CA068438-09
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen
  • [Other-IDs] NLM/ NIHMS453789; NLM/ PMC3616375
  •  go-up   go-down


31. Shen Z, Shen T, Wientjes MG, O'Donnell MA, Au JL: Intravesical treatments of bladder cancer: review. Pharm Res; 2008 Jul;25(7):1500-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravesical treatments of bladder cancer: review.
  • For bladder cancer, intravesical chemo/immunotherapy is widely used as adjuvant therapies after surgical transurethal resection, while systemic therapy is typically reserved for higher stage, muscle-invading, or metastatic diseases.
  • To our knowledge, intravesical therapy of bladder cancer represents the first example where computational pharmacological approach was used to design, and successfully predicted the outcome of, a randomized phase III trial (using mitomycin C).

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Urol Nephrol. 1999;31(4):451-6 [10668939.001]
  • [Cites] Gene Ther. 2000 Jan;7(1):31-4 [10680013.001]
  • [Cites] J Urol. 2000 Mar;163(3):761-7 [10687972.001]
  • [Cites] Urol Clin North Am. 2000 Feb;27(1):147-55 [10696253.001]
  • [Cites] Eur Urol. 2000;37 Suppl 3:45-9 [10828687.001]
  • [Cites] Gene Ther. 2000 May;7(10):844-51 [10845722.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8658-63 [10890892.001]
  • [Cites] Eur J Cancer. 2000 Jul;36 Suppl 2:34-7 [10908847.001]
  • [Cites] Urology. 2000 Aug 1;56(2):232-5 [10925084.001]
  • [Cites] Clin Infect Dis. 2000 Sep;31 Suppl 3:S109-14 [11010835.001]
  • [Cites] BJU Int. 2000 Oct;86(6):644-7 [11069370.001]
  • [Cites] Clin Cancer Res. 2000 Nov;6(11):4422-31 [11106263.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):597-604 [11309436.001]
  • [Cites] Gene Ther. 2001 Jan;8(1):41-8 [11402300.001]
  • [Cites] Eur Urol. 2001 Jun;39(6):643-7 [11464052.001]
  • [Cites] Oncol Rep. 2001 Sep-Oct;8(5):955-64 [11496299.001]
  • [Cites] J Tongji Med Univ. 2001;21(2):145-8 [11523222.001]
  • [Cites] J Urol. 2004 Mar;171(3):1324-9 [14767342.001]
  • [Cites] Pharm Res. 2004 May;21(5):832-7 [15180342.001]
  • [Cites] Eur Urol. 2004 Jul;46(1):65-71; discussion 71-2 [15183549.001]
  • [Cites] Cancer Gene Ther. 2004 Sep;11(9):594-602 [15272313.001]
  • [Cites] Int J Oncol. 2004 Oct;25(4):1065-71 [15375557.001]
  • [Cites] Mol Ther. 2004 Oct;10(4):697-705 [15451454.001]
  • [Cites] J Urol. 1971 Jul;106(1):72-4 [4998357.001]
  • [Cites] Urol Res. 1976 Apr 21;4(1):9-13 [821200.001]
  • [Cites] Radiology. 1977 May;123(2):475-82 [847220.001]
  • [Cites] Cancer Clin Trials. 1979 Winter;2(4):335-8 [394869.001]
  • [Cites] J Am Osteopath Assoc. 1983 Apr;82(8):570-3 [6682842.001]
  • [Cites] J Pharm Sci. 1983 May;72(5):549-53 [6864504.001]
  • [Cites] Cancer Res. 1984 Oct;44(10):4312-6 [6432309.001]
  • [Cites] J Surg Oncol. 1984 Sep;27(1):67-9 [6434883.001]
  • [Cites] J Surg Oncol. 1985 Apr;28(4):304-7 [3884905.001]
  • [Cites] J Urol. 1986 Apr;135(4):845-6 [3083122.001]
  • [Cites] Urology. 1987 Apr;29(4 Suppl):17-21 [3551281.001]
  • [Cites] Urology. 1988 Mar;31(3 Suppl):26-9 [3126592.001]
  • [Cites] Int J Hyperthermia. 1988 Mar-Apr;4(2):143-58 [3283266.001]
  • [Cites] Actas Urol Esp. 1988 Sep-Oct;12(5):424-9 [3146214.001]
  • [Cites] Urologe A. 1989 Mar;28(2):99-102 [2655259.001]
  • [Cites] J Urol. 1990 Mar;143(3):502-6 [2106041.001]
  • [Cites] Br J Urol. 1990 May;65(5):478-82 [2354313.001]
  • [Cites] Surg Gynecol Obstet. 1990 Dec;171(6):493-6 [2244283.001]
  • [Cites] J Chemother. 1990 Dec;2(6):397-400 [2093114.001]
  • [Cites] Ann Oncol. 1991 Feb;2(2):137-40 [2054316.001]
  • [Cites] J Natl Cancer Inst. 1992 Apr 1;84(7):510-5 [1545441.001]
  • [Cites] Int J Cancer. 1992 May 28;51(3):359-64 [1592527.001]
  • [Cites] Anticancer Drugs. 1992 May;3 Suppl 1:33-7 [1611115.001]
  • [Cites] Urol Res. 1992;20(3):233-6 [1615585.001]
  • [Cites] Eur Urol. 1992;21(3):206-10 [1499626.001]
  • [Cites] Eur Urol. 1992;22(2):112-4 [1478224.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1993;5(1):25-9 [8424911.001]
  • [Cites] Ann Oncol. 1993 Apr;4(4):313-6 [8518222.001]
  • [Cites] Cancer Res. 1993 Jul 15;53(14):3314-20 [8324743.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;32(4):255-62 [8324866.001]
  • [Cites] Urologe A. 1994 Mar;33(2):138-43 [8178408.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3325-8 [8012943.001]
  • [Cites] J Urol. 1994 Aug;152(2 Pt 1):374-8 [8015074.001]
  • [Cites] Cancer Immunol Immunother. 1994 Jul;39(1):68-70 [8044829.001]
  • [Cites] Anticancer Res. 1996 Mar-Apr;16(2):979-80 [8687163.001]
  • [Cites] Pharm Res. 1996 Dec;13(12):1887-91 [8987090.001]
  • [Cites] Science. 1997 Feb 28;275(5304):1320-3 [9036860.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):875-80 [9041189.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3352-6 [9096397.001]
  • [Cites] Urol Res. 1997;25(2):117-20 [9144878.001]
  • [Cites] J Urol. 1997 Aug;158(2):378-84 [9224307.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;40(4):285-92 [9225946.001]
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3394-8 [9363871.001]
  • [Cites] Urology. 1998 Mar;51(3):506-9 [9510365.001]
  • [Cites] J Urol. 1998 Aug;160(2):612-4 [9679938.001]
  • [Cites] J Urol. 1998 Nov;160(5):1668-71; discussion 1671-2 [9783928.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):978-85 [15761500.001]
  • [Cites] J Urol. 2005 Jul;174(1):322-7 [15947683.001]
  • [Cites] Br J Cancer. 2005 Jun 20;92(12):2140-7 [15928663.001]
  • [Cites] Urology. 2005 Jul;66(1):224-9 [15992886.001]
  • [Cites] Hum Gene Ther. 2005 Aug;16(8):937-46 [16076252.001]
  • [Cites] Urology. 2005 Aug;66(2):461-6 [16040105.001]
  • [Cites] Am J Ophthalmol. 2005 Oct;140(4):585-97 [16226510.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Feb;57(3):328-34 [16028098.001]
  • [Cites] Lancet Oncol. 2006 Jan;7(1):43-51 [16389183.001]
  • [Cites] J Med Chem. 2006 Jan 12;49(1):349-57 [16392819.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):305-13 [16397056.001]
  • [Cites] Urol Int. 2006;76(2):106-11 [16493208.001]
  • [Cites] Cancer Gene Ther. 2006 Feb;13(2):125-30 [16082384.001]
  • [Cites] Cancer Invest. 2006 Mar;24(2):160-3 [16537185.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2729-34 [16782913.001]
  • [Cites] Urol Oncol. 2006 Jul-Aug;24(4):344-8 [16818189.001]
  • [Cites] Biol Pharm Bull. 2006 Aug;29(8):1685-91 [16880626.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Oct;21(10):1538-43 [16928214.001]
  • [Cites] Int J Pharm. 2006 Sep 28;322(1-2):52-9 [16806751.001]
  • [Cites] Radiother Oncol. 2006 Oct;81(1):9-17 [17011058.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2006 Dec;75(6):367-73 [16930970.001]
  • [Cites] Oncol Rep. 2006 Dec;16(6):1381-8 [17089065.001]
  • [Cites] Chin Med J (Engl). 2006 Oct 20;119(20):1734-9 [17097022.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11219-27 [17145867.001]
  • [Cites] J Surg Res. 2007 Jan;137(1):1-9 [17161985.001]
  • [Cites] J Urol. 2001 Oct;166(4):1291-5 [11547060.001]
  • [Cites] J Urol. 2001 Oct;166(4):1300-4, discussion 1304-5 [11547062.001]
  • [Cites] Gan To Kagaku Ryoho. 2002 Jan;29(1):73-80 [11816482.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):957-65 [11844817.001]
  • [Cites] Immunol Lett. 2002 May 1;81(3):235-8 [11947931.001]
  • [Cites] J Urol. 2002 Aug;168(2):813-8 [12131373.001]
  • [Cites] Scand J Urol Nephrol. 2002;36(3):218-22 [12201939.001]
  • [Cites] Nat Biotechnol. 2002 Oct;20(10):1006-10 [12244328.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Oct;50(4):266-70 [12357299.001]
  • [Cites] BJU Int. 2002 Dec;90(9):957-64 [12460364.001]
  • [Cites] J Urol. 2003 Jan;169(1):90-5 [12478111.001]
  • [Cites] J Urol. 2003 Jan;169(1):357-60 [12478189.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 1994 Sep;85(9):1353-62 [7967297.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;35 Suppl:S81-3 [7994793.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;35 Suppl:S88-92 [7994795.001]
  • [Cites] J Urol. 1995 Mar;153(3 Pt 2):926-8 [7853576.001]
  • [Cites] J Urol. 1995 Mar;153(3 Pt 2):959-63 [7853583.001]
  • [Cites] J Urol. 1995 Mar;153(3 Pt 2):964-73 [7853584.001]
  • [Cites] J Urol. 1995 Jul;154(1):66-8 [7776458.001]
  • [Cites] Int J Urol. 1995 May;2(2):100-3 [7553280.001]
  • [Cites] J Urol. 1995 Dec;154(6):2050-3 [7500456.001]
  • [Cites] J Urol. 1996 Feb;155(2):753-6 [8558719.001]
  • [Cites] Cancer Chemother Pharmacol. 1996;37(6):539-46 [8612307.001]
  • [Cites] J Urol. 1996 Jul;156(1):56-9; discussion 59-60 [8648837.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):363-9 [12538489.001]
  • [Cites] J Intern Med. 2003 Jan;253(1):46-75 [12588538.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1291-300 [12684397.001]
  • [Cites] Int J Pharm. 2003 Apr 30;256(1-2):167-73 [12695023.001]
  • [Cites] Drugs R D. 2003;4(3):194-7 [12757408.001]
  • [Cites] Eur Urol. 2003 Jun;43(6):637-45 [12767365.001]
  • [Cites] Can J Urol. 2003 Apr;10(2):1790-5 [12773228.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Jun;51(6):445-50 [12802508.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2247-53 [12805322.001]
  • [Cites] J Immunother. 2003 Jul-Aug;26(4):343-8 [12843796.001]
  • [Cites] J Urol. 2003 Sep;170(3):777-82 [12913696.001]
  • [Cites] Urol Oncol. 2003 Sep-Oct;21(5):354-60 [14670544.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1208-12 [9849481.001]
  • [Cites] Clin Cancer Res. 1997 Jun;3(6):901-9 [9815765.001]
  • [Cites] Urology. 1999 May;53(5):1049-53 [10223504.001]
  • [Cites] Lancet. 1999 Mar 20;353(9157):947-54 [10459902.001]
  • [Cites] Cancer. 1999 Oct 1;86(7):1329-34 [10506721.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4912-8 [10519404.001]
  • [Cites] Nucleic Acids Res. 2004;32(19):e149 [15520458.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7244-51 [15534098.001]
  • [Cites] J Urol. 2005 Feb;173(2):604-9 [15643273.001]
  • [Cites] Cancer Immunol Immunother. 2005 May;54(5):414-23 [15565330.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):585-9 [15734775.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2243-50 [15781637.001]
  • (PMID = 18369709.001).
  • [ISSN] 0724-8741
  • [Journal-full-title] Pharmaceutical research
  • [ISO-abbreviation] Pharm. Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R21 CA111770; United States / NCI NIH HHS / CA / R21CA111770
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 154
  • [Other-IDs] NLM/ PMC2440939
  •  go-up   go-down


32. Naguleswaran A, Spicher M, Vonlaufen N, Ortega-Mora LM, Torgerson P, Gottstein B, Hemphill A: In vitro metacestodicidal activities of genistein and other isoflavones against Echinococcus multilocularis and Echinococcus granulosus. Antimicrob Agents Chemother; 2006 Nov;50(11):3770-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These findings demonstrate that synthetic isoflavones exhibit distinct in vitro effects on Echinococcus metacestodes and protoscoleces, which could potentially be exploited further for the development of novel chemotherapeutical tools against larval-stage Echinococcus infection.

  • Hazardous Substances Data Bank. GENISTEIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Environ Health Perspect. 2000 Oct;108(10):961-6 [11049816.001]
  • [Cites] Int J Parasitol. 2006 Sep;36(10-11):1097-112 [16793045.001]
  • [Cites] Antimicrob Agents Chemother. 2001 Aug;45(8):2256-62 [11451682.001]
  • [Cites] Phytochemistry. 2002 Jun;60(3):205-11 [12031439.001]
  • [Cites] J Parasitol. 2002 Feb;88(1):163-70 [12053958.001]
  • [Cites] Antimicrob Agents Chemother. 2002 Jul;46(7):2116-23 [12069963.001]
  • [Cites] Trends Parasitol. 2002 Oct;18(10):445-51 [12377595.001]
  • [Cites] Antimicrob Agents Chemother. 2003 Feb;47(2):467-74 [12543645.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6C):3811-7 [12552999.001]
  • [Cites] Antimicrob Agents Chemother. 2003 Nov;47(11):3586-91 [14576122.001]
  • [Cites] Gene. 2003 Dec 24;323:57-65 [14659879.001]
  • [Cites] Clin Microbiol Rev. 2004 Jan;17(1):107-35 [14726458.001]
  • [Cites] Hepatology. 2004 Feb;39(2):509-17 [14768005.001]
  • [Cites] J Antimicrob Chemother. 2004 Sep;54(3):609-16 [15282238.001]
  • [Cites] Parasitol Int. 2004 Dec;53(4):287-91 [15464437.001]
  • [Cites] Anal Biochem. 1984 Apr;138(1):141-3 [6731838.001]
  • [Cites] J Antimicrob Chemother. 1986 Dec;18(6):687-91 [3818494.001]
  • [Cites] Ann Trop Med Parasitol. 1988 Feb;82(1):65-6 [3401071.001]
  • [Cites] Methods Enzymol. 1991;201:362-70 [1658553.001]
  • [Cites] BMJ. 1992 Sep 12;305(6854):609-13 [1393072.001]
  • [Cites] Parasitol Res. 1995;81(7):605-14 [7479653.001]
  • [Cites] Ann Med. 1997 Apr;29(2):95-120 [9187225.001]
  • [Cites] J Med Chem. 1999 Mar 25;42(6):1018-26 [10090785.001]
  • [Cites] Antimicrob Agents Chemother. 1999 May;43(5):1052-61 [10223913.001]
  • [Cites] EMBO J. 1999 Sep 1;18(17):4608-18 [10469641.001]
  • [Cites] Comp Biochem Physiol C Toxicol Pharmacol. 2004 Oct;139(1-3):141-6 [15556076.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3470-8 [15833883.001]
  • [Cites] Nat Prod Rep. 2005 Aug;22(4):504-15 [16047048.001]
  • [Cites] Environ Health Perspect. 2000 Jun;108(6):487-93 [10856020.001]
  • [Cites] J Ethnopharmacol. 2000 Nov;73(1-2):131-5 [11025148.001]
  • [Cites] Antimicrob Agents Chemother. 2005 Sep;49(9):3715-23 [16127045.001]
  • [Cites] Antimicrob Agents Chemother. 2005 Nov;49(11):4628-34 [16251305.001]
  • [Cites] Antimicrob Agents Chemother. 2006 Jan;50(1):162-70 [16377682.001]
  • [Cites] Parasitol Int. 2006;55 Suppl:S15-21 [16343987.001]
  • [Cites] Expert Opin Pharmacother. 2006 May;7(7):953-64 [16634717.001]
  • [Cites] Parasitol Res. 2001 Jun;87(6):510-2 [11411955.001]
  • (PMID = 16954323.001).
  • [ISSN] 0066-4804
  • [Journal-full-title] Antimicrobial agents and chemotherapy
  • [ISO-abbreviation] Antimicrob. Agents Chemother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticestodal Agents; 0 / Isoflavones; 62229-50-9 / Epidermal Growth Factor; DH2M523P0H / Genistein; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.4.- / Metalloproteases
  • [Other-IDs] NLM/ PMC1635224
  •  go-up   go-down


33. Schöllnberger H, Stewart RD, Mitchel RE: Low-LET-induced radioprotective mechanisms within a stochastic two-stage cancer model. Dose Response; 2005;3(4):508-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-LET-induced radioprotective mechanisms within a stochastic two-stage cancer model.
  • A stochastic two-stage cancer model with clonal expansion was used to investigate the potential impact on human lung cancer incidence of some aspects of the hormesis mechanisms suggested by Feinendegen (Health Phys.
  • Sensitivity studies were conducted to identify critical model inputs and to help define the changes in cellular defense mechanisms necessary to produce a lifetime probability for lung cancer that deviates from a linear no-threshold (LNT) type of response.
  • Our studies suggest that lung cancer risk predictions may be very sensitive to the induction of DNA damage by endogenous processes.
  • For an additional lifetime dose of 1 Gy from low-LET radiation, endogenous processes may still account for as much as 20% of the predicted cancers (Fig. 2).
  • When both repair and scavengers are considered as inducible, radiation must enhance DNA repair and radical scavenging in excess of 30 to 40% of the baseline values to produce lifetime probabilities for lung cancer outside the range expected for endogenous processes and background radiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2001 Mar 2;84(5):674-9 [11237389.001]
  • [Cites] Radiat Res. 2002 Aug;158(2):181-6 [12105988.001]
  • [Cites] Int J Radiat Biol. 2000 Oct;76(10):1365-75 [11057745.001]
  • [Cites] Radiat Res. 2000 Aug;154(2):178-86 [10931690.001]
  • [Cites] Mutat Res. 2000 Jan 17;447(1):73-116 [10686307.001]
  • [Cites] Mutat Res. 1999 Sep 13;435(1):43-61 [10526216.001]
  • [Cites] Int J Radiat Biol. 1999 Sep;75(9):1189-99 [10528927.001]
  • [Cites] Radiat Res. 1999 Sep;152(3):273-9 [10453088.001]
  • [Cites] Radiat Environ Biophys. 1999 May;38(1):57-71 [10384956.001]
  • [Cites] Science. 1998 May 15;280(5366):1066-9 [9582118.001]
  • [Cites] Radiat Res. 1998 May;149(5):517-20 [9588363.001]
  • [Cites] Radiat Environ Biophys. 1997 Jun;36(2):85-8 [9271795.001]
  • [Cites] Risk Anal. 1997 Jun;17(3):391-9 [9232020.001]
  • [Cites] Radiat Environ Biophys. 1997 Feb;36(1):45-58 [9128898.001]
  • [Cites] Radiat Environ Biophys. 1996 May;35(2):127-9 [8792461.001]
  • [Cites] Radiat Res. 1996 Nov;146(5):582-5 [8896586.001]
  • [Cites] Radiat Res. 1996 Oct;146(4):369-73 [8927708.001]
  • [Cites] Mutat Res. 1996 Sep 23;356(2):209-16 [8841487.001]
  • [Cites] Histol Histopathol. 1996 Jan;11(1):237-55 [8720467.001]
  • [Cites] Biometrics. 1995 Dec;51(4):1278-91 [8589222.001]
  • [Cites] Risk Anal. 1994 Dec;14(6):1079-80 [7846315.001]
  • [Cites] Radiat Res. 1994 Feb;137(2 Suppl):S68-97 [8127953.001]
  • [Cites] Radiat Res. 1994 Feb;137(2 Suppl):S17-67 [8127952.001]
  • [Cites] Risk Anal. 1993 Jun;13(3):273-9 [8341806.001]
  • [Cites] Free Radic Biol Med. 1991;11(3):299-306 [1937147.001]
  • [Cites] N Engl J Med. 1989 Nov 9;321(19):1285-9 [2797101.001]
  • [Cites] Risk Anal. 1990 Jun;10(2):323-41 [2195604.001]
  • [Cites] J Natl Cancer Inst. 1981 Jun;66(6):1037-52 [6941039.001]
  • [Cites] J Natl Cancer Inst. 1978 Jul;61(1):49-52 [276637.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):13761-6 [14610281.001]
  • [Cites] Int J Radiat Biol. 2003 Apr;79(4):235-40 [12775447.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5057-62 [12679524.001]
  • [Cites] Br J Cancer. 2003 Mar 10;88(5):767-74 [12618888.001]
  • [Cites] Nature. 2003 Feb 13;421(6924):691-2 [12610596.001]
  • [Cites] Radiat Res. 2003 Mar;159(3):433-6 [12600247.001]
  • [Cites] Ann ICRP. 2006;36(1-2):25-327, iii [17188183.001]
  • [Cites] Risk Anal. 2001 Feb;21(1):103-5 [11332539.001]
  • [Cites] Radiat Res. 2001 Dec;156(6):700-7 [11741493.001]
  • [Cites] Radiat Res. 2003 Mar;159(3):320-7 [12600234.001]
  • [Cites] Int J Radiat Biol. 2002 Dec;78(12):1139-47 [12556341.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6B):4115-39 [11205238.001]
  • (PMID = 18648628.001).
  • [ISSN] 1559-3258
  • [Journal-full-title] Dose-response : a publication of International Hormesis Society
  • [ISO-abbreviation] Dose Response
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2477198
  • [Keywords] NOTNLM ; LNT / endogenous damage / hormesis / low-LET / lung cancer / radioprotective mechanisms / threshold
  •  go-up   go-down


34. Jun YW, Sheikholeslami S, Hostetter DR, Tajon C, Craik CS, Alivisatos AP: Continuous imaging of plasmon rulers in live cells reveals early-stage caspase-3 activation at the single-molecule level. Proc Natl Acad Sci U S A; 2009 Oct 20;106(42):17735-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Continuous imaging of plasmon rulers in live cells reveals early-stage caspase-3 activation at the single-molecule level.
  • These "crown nanoparticle plasmon rulers" allowed us to continuously monitor trajectories of caspase-3 activity in live cells for over 2 h, providing sufficient time to observe early-stage caspase-3 activation, which was not possible by conventional ensemble analyses.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GOLD, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13021-6 [11087856.001]
  • [Cites] Science. 2008 Oct 17;322(5900):442-6 [18927393.001]
  • [Cites] Nature. 2001 Jan 4;409(6816):113-5 [11343125.001]
  • [Cites] Nat Rev Cancer. 2002 Apr;2(4):277-88 [12001989.001]
  • [Cites] Nature. 2002 Oct 10;419(6907):638-41 [12374984.001]
  • [Cites] Science. 2003 Jun 27;300(5628):2061-5 [12791999.001]
  • [Cites] Cell Death Differ. 2003 Aug;10(8):881-8 [12867995.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):534-9 [14704266.001]
  • [Cites] J Am Chem Soc. 2004 Feb 11;126(5):1324-5 [14759174.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Jul;84(14):4910-3 [3474634.001]
  • [Cites] J Cell Sci. 1993 Oct;106 ( Pt 2):565-77 [7980739.001]
  • [Cites] J Biol Chem. 1997 Apr 11;272(15):9677-82 [9092497.001]
  • [Cites] J Biol Chem. 1997 Jul 18;272(29):17907-11 [9218414.001]
  • [Cites] Nat Cell Biol. 2000 Mar;2(3):168-72 [10707088.001]
  • [Cites] Science. 2000 Jun 16;288(5473):2048-51 [10856219.001]
  • [Cites] J Biol Chem. 1998 Apr 17;273(16):9842-51 [9545324.001]
  • [Cites] Science. 1998 Apr 24;280(5363):585-90 [9554849.001]
  • [Cites] Science. 1998 Sep 25;281(5385):2013-6 [9748157.001]
  • [Cites] Anal Biochem. 1998 Sep 10;262(2):157-76 [9750129.001]
  • [Cites] Annu Rev Biochem. 1998;67:509-44 [9759496.001]
  • [Cites] J Biol Chem. 1998 Oct 16;273(42):27364-73 [9765264.001]
  • [Cites] Science. 1998 Dec 4;282(5395):1877-82 [9836635.001]
  • [Cites] Science. 1999 Mar 12;283(5408):1676-83 [10073925.001]
  • [Cites] Science. 1999 Mar 12;283(5408):1689-95 [10073927.001]
  • [Cites] J Biol Chem. 2004 Dec 24;279(52):54275-82 [15494398.001]
  • [Cites] Nat Biotechnol. 2005 Jun;23(6):741-5 [15908940.001]
  • [Cites] Cell. 2005 Jun 17;121(6):937-50 [15960980.001]
  • [Cites] Bioconjug Chem. 2005 Sep-Oct;16(5):1176-80 [16173795.001]
  • [Cites] J Am Chem Soc. 2006 Feb 15;128(6):2115-20 [16464114.001]
  • [Cites] Science. 2006 Apr 14;312(5771):217-24 [16614209.001]
  • [Cites] EMBO J. 2006 Sep 20;25(18):4215-22 [16946702.001]
  • [Cites] Nat Methods. 2006 Nov;3(11):891-3 [17013382.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2667-72 [17307879.001]
  • [Cites] J Biol Chem. 2007 Sep 28;282(39):28960-70 [17686764.001]
  • [Cites] Cell Death Differ. 2008 Feb;15(2):322-31 [17975551.001]
  • [Cites] Mol Cell. 2008 Apr 11;30(1):11-25 [18406323.001]
  • [Cites] Oncogene. 2008 Oct 9;27(46):6012-22 [18560353.001]
  • [Cites] Cell Death Differ. 2001 Jan;8(1):38-43 [11313701.001]
  • (PMID = 19805121.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA128765; United States / NCI NIH HHS / CA / CA72006; United States / NIGMS NIH HHS / GM / 1 R25 GM56847; United States / NIGMS NIH HHS / GM / R01 GM077856; United States / NIGMS NIH HHS / GM / R01-GM77856; United States / NIGMS NIH HHS / GM / R25 GM056847; United States / NCI NIH HHS / CA / P01 CA072006; United States / NCI NIH HHS / CA / R01 CA128765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Molecular Probes; 7440-57-5 / Gold; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ PMC2764940
  •  go-up   go-down


35. Gottlieb B, Beitel LK, Alvarado C, Trifiro MA: Selection and mutation in the "new" genetics: an emerging hypothesis. Hum Genet; 2010 Mar;127(5):491-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This highly specialized form of somatic mosaicism has been found within both cancer and normal tissues.
  • If such genetic variation within individual tissues is widespread, it will need to be considered as a significant factor in the ontogeny of many multifactorial diseases, including cancer.
  • We, therefore, are proposing a hypothesis to explain multifactorial disease ontogeny in which pre-existing multiple somatic gene variants, which may arise at a very early stage of tissue development, are eventually selected due to changes in tissue microenvironments.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2007 Mar 8;446(7132):145-6 [17344839.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8514-8 [16166332.001]
  • [Cites] Nature. 2010 Jan 14;463(7278):191-6 [20016485.001]
  • [Cites] Genome Res. 2009 May;19(5):693-9 [19411593.001]
  • [Cites] PLoS One. 2008;3(10):e3444 [18941616.001]
  • [Cites] Genome Biol. 2009;10(3):R32 [19327155.001]
  • [Cites] Nat Biotechnol. 2009 Sep;27(9):847-50 [19668243.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18238-42 [17108085.001]
  • [Cites] J Evol Biol. 2004 Nov;17(6):1180-1; discussion 1192-4 [15525398.001]
  • [Cites] J Evol Biol. 2004 Nov;17(6):1167-77 [15525396.001]
  • [Cites] Hum Mol Genet. 1995 Apr;4(4):523-7 [7633399.001]
  • [Cites] Nature. 2010 Jan 14;463(7278):184-90 [20016488.001]
  • [Cites] Bioessays. 2007 Jul;29(7):678-85 [17563087.001]
  • [Cites] Aquat Toxicol. 2010 Jan 31;96(2):130-4 [19883946.001]
  • [Cites] Genome Res. 2009 Sep;19(9):1622-9 [19470904.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Aug;94(8):3025-30 [19470619.001]
  • [Cites] J Mol Evol. 2009 May;68(5):516-27 [19407924.001]
  • [Cites] Eur J Hum Genet. 2007 Mar;15(3):272-8 [17213840.001]
  • [Cites] Mod Pathol. 2005 Aug;18(8):1022-6 [15861213.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13081-6 [18723673.001]
  • [Cites] Hum Mutat. 2004 Jun;23(6):527-33 [15146455.001]
  • [Cites] Immunol Res. 2009;44(1-3):127-31 [19129986.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2009 Mar 12;364(1517):595-603 [19008194.001]
  • [Cites] Clin Vaccine Immunol. 2009 Nov;16(11):1615-23 [19776199.001]
  • [Cites] Crit Rev Biochem Mol Biol. 2007 Jul-Aug;42(4):247-58 [17687667.001]
  • [Cites] Nat Rev Genet. 2009 Jan;10(1):9-18 [19065136.001]
  • [Cites] Mutat Res. 2003 Mar;543(2):125-36 [12644182.001]
  • [Cites] Genome Res. 2009 Sep;19(9):1527-41 [19546169.001]
  • [Cites] Nature. 2009 Jul 23;460(7254):510-4 [19578359.001]
  • [Cites] J Evol Biol. 2004 Nov;17(6):1184-6; discussion 1192-4 [15525400.001]
  • [Cites] Hum Mutat. 2009 Jul;30(7):1043-7 [19514060.001]
  • [Cites] Int J Epidemiol. 2006 Oct;35(5):1151-9 [16987840.001]
  • [Cites] Science. 2001 Feb 16;291(5507):1304-51 [11181995.001]
  • [Cites] Carcinogenesis. 2005 May;26(5):916-22 [15731168.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Jan 26;107 Suppl 1:1725-30 [19805033.001]
  • [Cites] Annu Rev Pathol. 2010;5:51-75 [19743960.001]
  • [Cites] Trends Genet. 2001 Feb;17(2):79-82 [11173116.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2007;10(4):360-8 [17440439.001]
  • [Cites] Cancer Res. 2009 May 15;69(10):4434-42 [19366804.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):17-23 [15652746.001]
  • [Cites] Scand J Gastroenterol. 2007 Sep;42(9):1045-53 [17710669.001]
  • [Cites] J Med Genet. 2009 Sep;46(9):648 [19724013.001]
  • [Cites] Genome Res. 2007 Aug;17(8):1195-201 [17600086.001]
  • [Cites] Hum Mutat. 2009 Jun;30(6):1012-20 [19347965.001]
  • [Cites] Health Care Anal. 2001;9(1):1-13 [11372571.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D820-4 [17986460.001]
  • [Cites] Nature. 2001 Feb 15;409(6822):860-921 [11237011.001]
  • (PMID = 20099069.001).
  • [ISSN] 1432-1203
  • [Journal-full-title] Human genetics
  • [ISO-abbreviation] Hum. Genet.
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Receptors, Androgen
  • [Number-of-references] 48
  •  go-up   go-down


36. Gervaz P, Lavertu S, Kazemba B, Pemberton JH, Haddock MG, Gunderson LL: Sphincter-preserving radiation therapy for rectal cancer: a simulation study using three-dimensional computerized technology. Colorectal Dis; 2006 Sep;8(7):570-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sphincter-preserving radiation therapy for rectal cancer: a simulation study using three-dimensional computerized technology.
  • This approach provides, in theory, a means to selectively subtract the anal sphincter from the high-dose field of irradiation in patients with stage II and III adenocarcinomas of the mid-rectum scheduled for low anterior resection (LAR).
  • HYPOTHESIS: Implementation of 3DXRT with sphincter blocking may be a feasible strategy to reduce the dose of radiation distributed to the anal canal without reduction in the dose distribution to the gross tumour volume (GTV) plus adequate margins.
  • METHODS: Pretreatment simulation CT scans of 10 patients with rectal cancers located between 5 and 10 cm from the anal verge were retrieved from a computerized database.
  • Radiation oncologists and colorectal surgeons defined the contours of the GTV and the anal sphincter, respectively, on successive CT scan slices.
  • RESULTS: The mean distance of tumours from the anal verge was 6.3 cm.
  • The mean volume of the anal sphincter was 16.1 +/- 3.5 cm(3).
  • By comparison the mean dose distributed to the anal sphincter was dramatically reduced by using a sphincter block (33.2 +/- 12 Gy vs 6.4 +/- 4.1 Gy, P < 0.001).
  • CONCLUSION: During a course of radiotherapy for most low- or mid-rectal cancers, the anal canal is included within the field of irradiation with a mean dose distribution to the sphincter of 33 Gy.
  • Evaluation of 3DXRT with full sphincter block (mid-rectum) and partial sphincter block (distal rectum) is a feasible strategy to decrease the volume of anal sphincter carried to full dose without reduction in dose to the GTV.
  • This approach, by minimizing treatment-induced damage to the anal sphincter, might improve functional outcome of LAR.
  • [MeSH-major] Anal Canal / radiation effects. Computer Simulation. Radiotherapy Planning, Computer-Assisted. Rectal Neoplasms / radiotherapy. Rectal Neoplasms / therapy

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16919108.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


37. Bartels PH, Krouse RS, Prasad AR, Yozwiak M, Liu Y, Bartels HG, Alberts DS: Actinic damage in histopathologically normal skin. Anal Quant Cytol Histol; 2008 Dec;30(6):316-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: Karyometry can detect and statistically secure changes in skin due to solar exposure at a stage at which the skin is histopathologically determined to be normal.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Quant Cytol Histol. 2001 Aug;23(4):300-12 [11531145.001]
  • [Cites] Anal Quant Cytol Histol. 2003 Dec;25(6):353-61 [14714302.001]
  • [Cites] Anal Quant Cytol Histol. 1998 Feb;20(1):21-8 [9513688.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):1996-2002 [15598753.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1689-95 [18583468.001]
  • (PMID = 19160696.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA027502; United States / NCI NIH HHS / CA / P01 CA027502
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS584881; NLM/ PMC4033610
  •  go-up   go-down


38. Maeda J, Hirano T, Ogiwara A, Akimoto S, Kawakami T, Fukui Y, Oka T, Gong Y, Guo R, Inada H, Nawa K, Kojika M, Suga Y, Ohira T, Mukai K, Kato H: Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy. Br J Cancer; 2008 Feb 12;98(3):596-603
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy.
  • Although postoperative adjuvant chemotherapy (PAC) with uracil-tegafur significantly improves the prognosis of patients with stage I lung adenocarcinoma, subset analysis has revealed that only 11.5% of patients with stage IB derive actual benefit from such therapy.
  • We performed comprehensive protein analysis of 24 surgically resected specimens of stage I adenocarcinoma using liquid chromatography-tandem mass spectrometry (LC-MS/MS), followed by bioinformatical investigations to identify protein molecules.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2001 May 18;105(4):425-31 [11371340.001]
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] J Natl Cancer Inst. 2003 Oct 1;95(19):1453-61 [14519751.001]
  • [Cites] Science. 2003 Dec 5;302(5651):1704-9 [14657486.001]
  • [Cites] N Engl J Med. 2004 Jan 22;350(4):351-60 [14736927.001]
  • [Cites] N Engl J Med. 2004 Apr 22;350(17):1713-21 [15102997.001]
  • [Cites] Lab Invest. 2004 Aug;84(8):999-1012 [15195114.001]
  • [Cites] J Pathol. 1996 Oct;180(2):175-80 [8976877.001]
  • [Cites] J Cell Biol. 1996 Dec;135(6 Pt 1):1643-54 [8978829.001]
  • [Cites] Am J Pathol. 1997 Feb;150(2):483-95 [9033265.001]
  • [Cites] Clin Cancer Res. 1998 Sep;4(9):2085-8 [9748123.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Proteomics. 2005 Mar;5(4):856-64 [15668996.001]
  • [Cites] N Engl J Med. 2005 Jun 23;352(25):2589-97 [15972865.001]
  • [Cites] Tumour Biol. 2005 May-Jun;26(3):153-7 [15970650.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):4999-5006 [16051951.001]
  • [Cites] J Biol Chem. 2006 Jan 13;281(2):677-80 [16243835.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Gan. 1979 Apr;70(2):209-14 [381088.001]
  • [Cites] Gan. 1979 Jun;70(3):353-9 [467897.001]
  • [Cites] Oncogene. 1993 Apr;8(4):999-1008 [8455951.001]
  • [Cites] Am J Clin Pathol. 1994 Aug;102(2):171-5 [8042584.001]
  • [Cites] BMJ. 1995 Oct 7;311(7010):899-909 [7580546.001]
  • [Cites] Nat Rev Cancer. 2002 Jun;2(6):442-54 [12189386.001]
  • (PMID = 18212748.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Vimentin; 1548R74NSZ / Tegafur; EC 3.6.1.- / Nonmuscle Myosin Type IIA
  • [Other-IDs] NLM/ PMC2243141
  •  go-up   go-down


39. Bemelman WA: Minimally invasive surgery for early lower GI cancer. Best Pract Res Clin Gastroenterol; 2005 Dec;19(6):993-1005
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimally invasive surgery for early lower GI cancer.
  • Two technical developments in colorectal surgery-i.e. transanal endoscopic microsurgery (TEM) and laparoscopic surgery for colorectal disease-are now available for the treatment of early lower GI cancer.
  • Benign lesions and early-stage tumours of the rectosigmoid are amenable for a transanal approach.
  • After installation of a pneumorectum, lesions up to 25 cm from the anal verge, including circumferential lesions, can be removed with a recurrence rate of 0-5% for adenomas, 3% for low-risk T1 carcinomas, and 8% for all carcinomas.
  • Early colonic cancer requires laparoscopic colectomy guided by preoperative colonoscopy or preoperative endoscopic tattooing for localisation of the affected segment.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16338654.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 57
  •  go-up   go-down


40. Jeon SH, Jeon SH, Chang SG: Clinical prognostic factors for radical cystectomy in bladder cancer. Cancer Res Treat; 2005 Feb;37(1):48-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical prognostic factors for radical cystectomy in bladder cancer.
  • PURPOSE: We investigated the effects of radical cystectomy and the prognostic factors that affect the survival of bladder cancer patients.
  • Indications for surgery included muscle invasive bladder cancer and high-risk superficial bladder cancer.
  • The cancer specific and recurrence free survival rates with respect to the possible prognostic factors were determined using Kaplan-Meier statistics.
  • Pathologic stage, tumor grade, mean nuclear area, sex and lymphatic invasion were significant factors by univariate analysis (p<0.05).
  • Multivariate analysis identified pathologic stage and lymphatic invasion as independent prognostic factors.
  • CONCLUSIONS: Radical cystectomy for organ-confined cancer showed favorable 5- and 10-year survival rates.
  • The most significant independent prognostic factors were the pathologic stage and the presence of lymphatic invasion, which were highly correlated with all the investigated disease endpoints.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1979 Jun;43(6):2532-9 [455239.001]
  • [Cites] J Korean Med Sci. 1992 Jun;7(2):154-61 [1524728.001]
  • [Cites] J Urol. 1991 Jan;145(1):45-50 [1984097.001]
  • [Cites] J Urol. 1991 Mar;145(3):459-64; discussion 464-7 [1997689.001]
  • [Cites] J Urol. 1983 Jul;130(1):56-60 [6864915.001]
  • [Cites] Urology. 1980 Aug;16(2):142-4 [7404907.001]
  • [Cites] Br J Cancer. 2004 Jun 1;90(11):2142-4 [15150549.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):666-75 [11157016.001]
  • [Cites] Anal Quant Cytol Histol. 2001 Aug;23(4):251-6 [11531139.001]
  • [Cites] BJU Int. 2002 Mar;89(4):374-8 [11872027.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):460-7 [11872337.001]
  • [Cites] Urology. 2002 Dec;60(6):1124-30 [12475695.001]
  • [Cites] Urol Int. 2004;72(2):103-11 [14963349.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):89-93 [11134199.001]
  • (PMID = 19956510.001).
  • [ISSN] 2005-9256
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2785423
  • [Keywords] NOTNLM ; Bladder cancer / Prognostic factor / Radical cystectomy
  •  go-up   go-down


41. Law WL, Chu KW: Outcomes of resection of stage IV rectal cancer with mesorectal excision. J Surg Oncol; 2006 Jun 1;93(7):523-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of resection of stage IV rectal cancer with mesorectal excision.
  • BACKGROUND: There is no consensus as to the management of the primary rectal cancer in the presence of distant metastasis and data on the outcomes of radical resection in stage IV rectal cancer are limited.
  • This study aims to evaluate the results of resection of rectal cancer in the patients with stage IV disease and to analyze the factors that might affect the survival of these patients.
  • METHODS: Of the 744 patients with radical resection of primary rectal and rectosigmoid cancer during the study period from August 1993 to July 2002, 70 had stage IV disease on the initial presentation.
  • The median level of the tumor from the anal verge was 10 cm (range 3-20 cm).
  • The median cancer-specific survival of the patients who survived the surgery was 15.2 months.
  • CONCLUSIONS: Postoperative mortality and morbidity were acceptable in patients with stage IV rectal cancer.

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16705728.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Beretta G, Furlanetto S, Regazzoni L, Zarrella M, Facino RM: Quenching of alpha,beta-unsaturated aldehydes by green tea polyphenols: HPLC-ESI-MS/MS studies. J Pharm Biomed Anal; 2008 Nov 4;48(3):606-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HNE is the most abundant and genotoxic product of oxidation of dietary polyunsaturated fatty acids, and is believed to be involved in the early stage of colorectal carcinogenesis on account of its genotoxic potential.
  • These results suggest that EGCG and green tea extract, beside the proposed mechanisms of chemoprevention that target multiple cell-signaling pathways that control cell proliferation and apoptosis in cancer cells, can also prevent protein carbonylation in the tumor tissue environment, depending on the pH of the medium surrounding the tissue, the type of tumor, the stage of dysregulation of lipid peroxidation and, finally, the stage of carcinoma development.

  • Hazardous Substances Data Bank. Green tea .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18619756.001).
  • [ISSN] 0731-7085
  • [Journal-full-title] Journal of pharmaceutical and biomedical analysis
  • [ISO-abbreviation] J Pharm Biomed Anal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aldehydes; 0 / Flavonoids; 0 / Phenols; 0 / Polyphenols; 0 / Tea
  •  go-up   go-down


43. Lee BY, Jethwaney D, Schilling B, Clemens DL, Gibson BW, Horwitz MA: The Mycobacterium bovis bacille Calmette-Guerin phagosome proteome. Mol Cell Proteomics; 2010 Jan;9(1):32-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our phagosome purification procedure and initial proteomics analyses set the stage for a quantitative comparative analysis of mycobacterial and latex bead phagosome proteomes.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Methods Cell Sci. 2000;22(4):329-41 [11549946.001]
  • [Cites] Biochem Cell Biol. 2001;79(6):719-28 [11800012.001]
  • [Cites] Histochem Cell Biol. 2001 Dec;116(6):507-17 [11810192.001]
  • [Cites] FASEB J. 2002 Apr;16(6):487-99 [11919151.001]
  • [Cites] Cell. 2002 Jul 12;110(1):119-31 [12151002.001]
  • [Cites] Infect Immun. 2002 Oct;70(10):5800-7 [12228310.001]
  • [Cites] J Cell Physiol. 2002 Nov;193(2):154-63 [12384992.001]
  • [Cites] Biochim Biophys Acta. 2003 Mar 10;1610(2):261-70 [12648779.001]
  • [Cites] J Biol Chem. 2003 Mar 28;278(13):10963-72 [12519789.001]
  • [Cites] Nat Rev Immunol. 2003 Apr;3(4):280-91 [12669019.001]
  • [Cites] Proteomics. 2003 Apr;3(4):536-48 [12687620.001]
  • [Cites] Arch Dermatol Res. 2003 Sep;295(5):203-10 [12898150.001]
  • [Cites] Nature. 2003 Sep 25;425(6956):402-6 [14508490.001]
  • [Cites] J Biol Chem. 2003 Oct 3;278(40):39104-13 [12860994.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12889-94 [14561893.001]
  • [Cites] J Biol Chem. 2003 Nov 21;278(47):46961-7 [12963735.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4336-44 [12881314.001]
  • [Cites] Arch Biochem Biophys. 2004 Jan 1;421(1):159-65 [14678797.001]
  • [Cites] Infect Immun. 2004 Jun;72(6):3204-17 [15155622.001]
  • [Cites] Gene. 2004 Jun 23;335:159-68 [15194199.001]
  • [Cites] Anal Chem. 2004 Jul 15;76(14):4193-201 [15253663.001]
  • [Cites] Curr Opin Cell Biol. 2004 Aug;16(4):415-21 [15261674.001]
  • [Cites] Traffic. 2004 Oct;5(10):785-97 [15355514.001]
  • [Cites] Proc Natl Acad Sci U S A. 1976 Jul;73(7):2510-4 [821057.001]
  • [Cites] Infect Immun. 1991 May;59(5):1823-31 [1902198.001]
  • [Cites] Diabetologia. 1992 Apr;35(4):316-24 [1516759.001]
  • [Cites] J Autoimmun. 1992 Aug;5(4):453-63 [1418289.001]
  • [Cites] Science. 1994 Feb 4;263(5147):678-81 [8303277.001]
  • [Cites] J Struct Biol. 1993 Nov-Dec;111(3):180-9 [7516175.001]
  • [Cites] J Immunol. 1994 Sep 15;153(6):2568-78 [8077667.001]
  • [Cites] Eur J Biochem. 1994 Nov 15;226(1):15-22 [7957243.001]
  • [Cites] J Cell Sci. 1994 Jun;107 ( Pt 6):1661-70 [7962206.001]
  • [Cites] J Exp Med. 1995 Jan 1;181(1):257-70 [7807006.001]
  • [Cites] Methods Cell Biol. 1994;45:261-76 [7707990.001]
  • [Cites] Trends Microbiol. 1996 Mar;4(3):113-8 [8868090.001]
  • [Cites] J Exp Med. 1996 Oct 1;184(4):1349-55 [8879207.001]
  • [Cites] J Biol Chem. 1997 May 16;272(20):13326-31 [9148954.001]
  • [Cites] J Cell Biochem. 1998 Jun 1;69(3):304-15 [9581869.001]
  • [Cites] Biochim Biophys Acta. 1999 Jul 13;1432(2):159-84 [10407139.001]
  • [Cites] Nat Biotechnol. 1999 Jul;17(7):676-82 [10404161.001]
  • [Cites] J Biol Chem. 2004 Nov 5;279(45):46835-42 [15337753.001]
  • [Cites] J Cell Sci. 2004 Dec 15;117(Pt 26):6297-311 [15561770.001]
  • [Cites] Mol Cell Proteomics. 2005 Jan;4(1):84-96 [15591592.001]
  • [Cites] Mol Cells. 2005 Feb 28;19(1):39-45 [15750338.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7111-20 [16103060.001]
  • [Cites] Cell. 2005 Oct 7;123(1):157-70 [16213220.001]
  • [Cites] Proteomics. 2005 Oct;5(15):3966-78 [16145712.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(2):727-34 [16382162.001]
  • [Cites] Blood. 2006 Apr 1;107(7):2728-35 [16357324.001]
  • [Cites] Mol Biol Cell. 2006 Apr;17(4):1514-26 [16421253.001]
  • [Cites] J Cell Sci. 2006 Apr 15;119(Pt 8):1494-503 [16537643.001]
  • [Cites] Trends Cell Biol. 2006 May;16(5):242-9 [16595175.001]
  • [Cites] Proteomics. 2006 Jun;6(11):3352-68 [16637015.001]
  • [Cites] J Cell Biol. 2006 Jun 5;173(5):767-80 [16754960.001]
  • [Cites] J Exp Med. 1971 Sep 1;134(3 Pt 1):713-40 [15776571.001]
  • [Cites] J Cell Sci. 2006 Aug 1;119(Pt 15):3149-60 [16835267.001]
  • [Cites] Cell Mol Life Sci. 2006 Aug;63(16):1823-32 [16699812.001]
  • [Cites] Biol Chem. 2006 Sep;387(9):1227-36 [16972791.001]
  • [Cites] Cell. 2006 Oct 6;127(1):157-70 [17018283.001]
  • [Cites] EMBO J. 2006 Nov 15;25(22):5250-9 [17082769.001]
  • [Cites] J Neurosci. 2007 Jan 3;27(1):190-202 [17202486.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):95-101 [17151602.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5596-601 [17372194.001]
  • [Cites] Traffic. 2007 Oct;8(10):1385-403 [17725553.001]
  • [Cites] J Immunol. 2007 Dec 15;179(12):8322-31 [18056377.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Jan;9(1):60-71 [18043707.001]
  • [Cites] Mol Microbiol. 2008 May;68(4):1047-60 [18363792.001]
  • [Cites] J Exp Med. 2009 Feb 16;206(2):399-410 [19153244.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3324-9 [19218463.001]
  • [Cites] PLoS Pathog. 2009 Apr;5(4):e1000374 [19360129.001]
  • [Cites] Eur J Cell Biol. 1999 Nov;78(11):802-12 [10604657.001]
  • [Cites] Electrophoresis. 1999 Dec;20(18):3551-67 [10612281.001]
  • [Cites] J Exp Med. 2000 Jan 17;191(2):287-302 [10637273.001]
  • [Cites] J Histochem Cytochem. 2000 Jan;48(1):45-56 [10653585.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3201-6 [10716730.001]
  • [Cites] Infect Immun. 2000 May;68(5):2671-84 [10768959.001]
  • [Cites] Infect Immun. 2000 Sep;68(9):5154-66 [10948139.001]
  • [Cites] J Cell Biol. 2001 Jan 8;152(1):165-80 [11149929.001]
  • [Cites] Mol Cell. 2001 Feb;7(2):421-32 [11239470.001]
  • [Cites] J Biol Chem. 2001 May 25;276(21):18507-12 [11279173.001]
  • [Cites] J Immunol. 2001 Jun 15;166(12):7309-18 [11390481.001]
  • (PMID = 19815536.001).
  • [ISSN] 1535-9484
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL077000; United States / NIAID NIH HHS / AI / U54 AI065359; United States / NIAID NIH HHS / AI / AI065359; United States / NHLBI NIH HHS / HL / HL077000
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / LAMP2 protein, human; 0 / Lysosomal-Associated Membrane Protein 2; 0 / Lysosome-Associated Membrane Glycoproteins; 0 / Membrane Glycoproteins; 0 / Membrane Proteins; 0 / NPC1 protein, human; 0 / Proteome; 0 / Qa-SNARE Proteins; 0 / flotillins; 147336-22-9 / Green Fluorescent Proteins; EC 3.6.1.- / Vacuolar Proton-Translocating ATPases
  • [Other-IDs] NLM/ PMC2808266
  •  go-up   go-down


44. Molenkamp BG, Vuylsteke RJ, van Leeuwen PA, Meijer S, Vos W, Wijnands PG, Scheper RJ, de Gruijl TD: Matched skin and sentinel lymph node samples of melanoma patients reveal exclusive migration of mature dendritic cells. Am J Pathol; 2005 Nov;167(5):1301-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we compare the frequency and activation state of human DCs between matched skin and sentinel lymph node (SLN) samples, after intradermal administration of either granulocyte/macrophage colony-stimulating factor (GM-CSF) or saline, at the excision site of stage I primary melanoma.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. SODIUM CHLORIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2003 Apr 1;170(7):3488-94 [12646609.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1057-65 [12637471.001]
  • [Cites] Nature. 1992 Nov 19;360(6401):258-61 [1279441.001]
  • [Cites] J Invest Dermatol. 1993 Mar;100(3):269S-273S [7680054.001]
  • [Cites] Br J Surg. 1994 Dec;81(12):1769-70 [7827935.001]
  • [Cites] Int J Cancer. 1997 Nov 4;73(3):309-16 [9359474.001]
  • [Cites] Br J Dermatol. 1998 Aug;139(2):239-46 [9767237.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):976-83 [10071292.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8456-60 [15548718.001]
  • [Cites] Annu Rev Immunol. 2000;18:767-811 [10837075.001]
  • [Cites] J Immunol. 2000 Nov 1;165(9):4910-6 [11046016.001]
  • [Cites] Immunol Rev. 2000 Oct;177:134-40 [11138771.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):604-8 [11406663.001]
  • [Cites] Trends Immunol. 2001 Jul;22(7):394-400 [11429324.001]
  • [Cites] J Immunol. 2001 Jul 15;167(2):741-8 [11441078.001]
  • [Cites] Anal Cell Pathol. 2001;22(3):143-9 [11455033.001]
  • [Cites] Melanoma Res. 2001 Aug;11(4):401-10 [11479429.001]
  • [Cites] J Exp Med. 2001 Sep 17;194(6):769-79 [11560993.001]
  • [Cites] Nat Immunol. 2001 Nov;2(11):1010-7 [11590405.001]
  • [Cites] Nat Immunol. 2001 Nov;2(11):988-9 [11685217.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):351-8 [11773639.001]
  • [Cites] Oncology (Williston Park). 2002 Jan;16(1 Suppl 1):27-31 [11829280.001]
  • [Cites] Am J Pathol. 2002 Jul;161(1):19-26 [12107085.001]
  • [Cites] J Exp Med. 2002 Aug 19;196(4):417-30 [12186835.001]
  • [Cites] Arch Dermatol Res. 1999 Feb-Mar;291(2-3):65-72 [10195392.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3238-44 [10506625.001]
  • [Cites] J Invest Dermatol. 2003 Feb;120(2):266-74 [12542532.001]
  • [Cites] Annu Rev Immunol. 2003;21:685-711 [12615891.001]
  • [Cites] J Clin Pathol. 2004 Jun;57(6):618-20 [15166267.001]
  • (PMID = 16251414.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD1; 0 / CD1a antigen; 0 / CD83 antigen; 0 / Immunoglobulins; 0 / Membrane Glycoproteins; 451W47IQ8X / Sodium Chloride; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  • [Other-IDs] NLM/ PMC1603792
  •  go-up   go-down


45. Yu J, Ohuchida K, Mizumoto K, Ishikawa N, Ogura Y, Yamada D, Egami T, Fujita H, Ohashi S, Nagai E, Tanaka M: Overexpression of c-met in the early stage of pancreatic carcinogenesis; altered expression is not sufficient for progression from chronic pancreatitis to pancreatic cancer. World J Gastroenterol; 2006 Jun 28;12(24):3878-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of c-met in the early stage of pancreatic carcinogenesis; altered expression is not sufficient for progression from chronic pancreatitis to pancreatic cancer.
  • METHODS: We used 46 bulk tissues and 36 micro-dissected samples, including normal pancreas, chronic pancreatitis, and pancreatic cancer, for quantitative real-time reverse transcription-polymerase chain reaction.
  • RESULTS: In bulk tissue analyses, pancreatic cancer tissues expressed significantly higher levels of c-met than did chronic pancreatitis and normal pancreas tissues. c-met levels did not differ between chronic pancreatitis and normal pancreas tissues.
  • In microdissection-based analyses, c-met was expressed at higher levels in microdissected pancreatic cancer cells and pancreatitis-affected epithelial cells than in normal ductal epithelial cells (both, P < 0.01).
  • Interestingly, pancreatitis-affected epithelial cells expressed levels of c-met similar to those of pancreatic cancer cells.
  • CONCLUSION: Overexpression of c-met occurs during the early stage of pancreatic carcinogenesis, and a single alteration of c-met expression is not sufficient for progression of chronic pancreatitis-affected epithelial cells to pancreatic cancer cells.


46. Widder J, Kastenberger R, Fercher E, Schmid R, Langendijk JA, Dobrowsky W, Pötter R: Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients. Radiother Oncol; 2008 Jun;87(3):367-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation dose associated with local control in advanced anal cancer: retrospective analysis of 129 patients.
  • BACKGROUND AND PURPOSE: To retrospectively analyse a large consecutive cohort of patients with anal cancer for treatment-related factors influencing local control and survival.
  • MATERIALS AND METHODS: All patients referred for primary radiotherapy at Medical University of Vienna in 1990-2002 with anal canal carcinoma without distant metastases were analysed.
  • RESULTS: Median age was 67 years (n=129), the UICC stage distribution was 15%, 58%, and 27% for stages I, II, and III, respectively.
  • Stage and age were significant factors for overall and colostomy-free-survival, N-stage for disease-free-survival.
  • Shorter overall treatment time favoured local control in stage T1-2 (p=.015), higher total radiation dose and female gender were associated with improved local control in T3-4 tumours (p=.021).
  • CONCLUSIONS: These results support potential improvement of anal cancer treatment by studying advanced technology such as IMRT, making it possible to tailor high-dose regions.
  • [MeSH-major] Anus Neoplasms / radiotherapy. Carcinoma, Squamous Cell / radiotherapy

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18501453.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


47. Thriveni K, Krishnamoorthy L, Ramaswamy G: Correlation study of Carcino Embryonic Antigen & Cancer Antigen 15.3 in pretreated female breast cancer patients. Indian J Clin Biochem; 2007 Mar;22(1):57-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation study of Carcino Embryonic Antigen & Cancer Antigen 15.3 in pretreated female breast cancer patients.
  • Carcino Embryonic Antigen (CEA) and Cancer Antigen 15.3 (CA15.3) are the most common tumor markers in breast cancer patients.
  • Serum levels of CEA and CA 15.3 were studied in female breast cancer patients prior to treatment.
  • To evaluate the utility of these markers, 207 Breast carcinoma patients belonging to all the stages were considered.
  • Measurement of serum CA 15.3 levels showed significant correlation (24.8%) with advanced stages and larger tumor sizes, whereas serum CEA levels did not show any significant correlation in breast cancer patients prior to treatment.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tumour Biol. 1995;16(4):243-53 [7604205.001]
  • [Cites] Indian J Clin Biochem. 2005 Jan;20(1):165-8 [23105517.001]
  • [Cites] Oncology. 1994 Nov-Dec;51(6):491-6 [7970492.001]
  • [Cites] Br J Cancer. 1991 Oct;64(4):757-63 [1911226.001]
  • [Cites] J Clin Lab Anal. 1991;5(5):344-66 [1941355.001]
  • [Cites] Cancer. 1991 Aug 1;68(3):574-82 [2065278.001]
  • [Cites] Biochim Biophys Acta. 1990 Dec 11;1032(2-3):177-89 [2261493.001]
  • [Cites] Hematol Oncol Clin North Am. 1989 Dec;3(4):653-74 [2691493.001]
  • [Cites] Anticancer Res. 1996 Mar-Apr;16(2):875-81 [8687144.001]
  • [Cites] J Exp Med. 1965 Mar 1;121:439-62 [14270243.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1314-20 [12142389.001]
  • [Cites] J Am Coll Surg. 1997 Jul;185(1):55-9 [9208961.001]
  • [Cites] Clin Chem. 2004 Mar;50(3):559-63 [14726467.001]
  • [Cites] Tumour Biol. 1998;19 Suppl 1:1-20 [9422084.001]
  • [Cites] Dis Colon Rectum. 1998 Sep;41(9):1127-33 [9749496.001]
  • [Cites] Ann Clin Biochem. 1999 Sep;36 ( Pt 5):579-86 [10505206.001]
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):979-94 [10888773.001]
  • [Cites] Int J Biol Markers. 2000 Oct-Dec;15(4):330-3 [11192829.001]
  • [Cites] Cancer. 2004 Oct 15;101(8):1767-75 [15386335.001]
  • [Cites] Int J Biol Markers. 1995 Jan-Mar;10(1):35-41 [7629425.001]
  • (PMID = 23105653.001).
  • [ISSN] 0970-1915
  • [Journal-full-title] Indian journal of clinical biochemistry : IJCB
  • [ISO-abbreviation] Indian J Clin Biochem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3454275
  • [Keywords] NOTNLM ; Breast cancer / Grade / Node / Tumor markers / Tumor size / stage
  •  go-up   go-down


48. Nock NL, Bock C, Neslund-Dudas C, Beebe-Dimmer J, Rundle A, Tang D, Jankowski M, Rybicki BA: Polymorphisms in glutathione S-transferase genes increase risk of prostate cancer biochemical recurrence differentially by ethnicity and disease severity. Cancer Causes Control; 2009 Dec;20(10):1915-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in glutathione S-transferase genes increase risk of prostate cancer biochemical recurrence differentially by ethnicity and disease severity.
  • Although the GSTM1 null genotype has been shown to increase prostate cancer mortality in Caucasians, potential associations between GST polymorphisms and prostate cancer biochemical recurrence (BCR) have not been well studied, particularly in African-Americans.
  • Similar associations were observed for advanced stage and more aggressive (high grade or advanced stage) disease.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 2003 Feb;61(2):365-9 [12597949.001]
  • [Cites] J Urol. 2003 Jan;169(1):157-63 [12478126.001]
  • [Cites] Am J Hum Genet. 2003 Jun;72(6):1492-1504 [12817591.001]
  • [Cites] J Urol. 2003 Apr;169(4):1320-4 [12629352.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 1996;36:203-32 [8725388.001]
  • [Cites] Biochemistry. 1996 Oct 22;35(42):13664-72 [8885846.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):176-81 [15668493.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2005;45:51-88 [15822171.001]
  • [Cites] Int J Cancer. 2005 Oct 20;117(1):8-13 [15880531.001]
  • [Cites] Prostate. 2006 Feb 1;66(2):146-56 [16173036.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1236-45 [17548691.001]
  • [Cites] Pathology. 2007 Jun;39(3):299-304 [17558856.001]
  • [Cites] J Urol. 2007 Oct;178(4 Pt 1):1271-6 [17698101.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):750-7 [18245535.001]
  • [Cites] Urology. 2008 Jan;71(1):161-7 [18242387.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Urol. 2008 Oct;180(4):1336-9; discussion 1340-1 [18707696.001]
  • [Cites] Prostate. 2006 Oct 1;66(14):1535-41 [16921513.001]
  • [Cites] Cancer Detect Prev. 2006;30(5):412-22 [17067754.001]
  • [Cites] In Vivo. 2000 Jan-Feb;14(1):173-82 [10757075.001]
  • [Cites] Cancer. 2000 May 1;88(9):2082-91 [10813720.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 7;93(3):219-25 [11158191.001]
  • [Cites] Cancer. 2002 Dec 1;95(11):2302-7 [12436435.001]
  • [Cites] Anal Biochem. 1996 Apr 5;236(1):184-6 [8619490.001]
  • (PMID = 19568698.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA129162-02; United States / NCI NIH HHS / CA / K07-CA129162; United States / NIEHS NIH HHS / ES / R01-ES011126; United States / NIEHS NIH HHS / ES / R01 ES011126; United States / NCI NIH HHS / CA / K07 CA129162-02; United States / NCI NIH HHS / CA / K07 CA129162
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


49. Little MP: Cancer models, genomic instability and somatic cellular Darwinian evolution. Biol Direct; 2010;5:19; discussion 19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer models, genomic instability and somatic cellular Darwinian evolution.
  • The biology of cancer is critically reviewed and evidence adduced that its development can be modelled as a somatic cellular Darwinian evolutionary process.
  • A variety of quasi-mechanistic models of carcinogenesis are reviewed, all based on this somatic Darwinian evolutionary hypothesis; in particular, the multi-stage model of Armitage and Doll (Br. J.
  • Cancer 1954:8;1-12), the two-mutation model of Moolgavkar, Venzon, and Knudson (MVK) (Math. Biosci.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiat Res. 2001 Jul;156(1):78-94 [11418076.001]
  • [Cites] Environ Mol Mutagen. 1993;22(4):245-9 [8223505.001]
  • [Cites] Cell. 1993 Dec 3;75(5):1027-38 [8252616.001]
  • [Cites] Cell. 1993 Dec 17;75(6):1215-25 [8261515.001]
  • [Cites] Science. 1994 Mar 18;263(5153):1625-9 [8128251.001]
  • [Cites] Nature. 1994 Mar 17;368(6468):258-61 [8145827.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1821-8 [7997877.001]
  • [Cites] Cancer Metastasis Rev. 1995 Mar;14(1):3-15 [7606818.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):545-60 [7677168.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14966-9 [14657359.001]
  • [Cites] Radiat Res. 2004 Jan;161(1):72-81 [14680394.001]
  • [Cites] Oncogene. 2004 Apr 12;23(16):2797-808 [15077143.001]
  • [Cites] J Theor Biol. 2004 Aug 7;229(3):395-411 [15234206.001]
  • [Cites] Cell Cycle. 2004 Mar;3(3):358-62 [14726709.001]
  • [Cites] Cancer Res. 1967 Aug;27(8):1325-40 [4860293.001]
  • [Cites] Radiat Res. 1968 Mar;33(3):620-43 [4867897.001]
  • [Cites] Proc Natl Acad Sci U S A. 1969 Nov;64(3):1087-94 [5264139.001]
  • [Cites] Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3 [5279523.001]
  • [Cites] Cancer Res. 1973 Dec;33(12):3061-8 [4357347.001]
  • [Cites] Science. 1976 Oct 1;194(4260):23-8 [959840.001]
  • [Cites] Virology. 1977 Feb;76(2):675-84 [190771.001]
  • [Cites] J Natl Cancer Inst. 1978 Jul;61(1):49-52 [276637.001]
  • [Cites] Hum Genet. 1979 Nov 1;52(1):1-54 [393614.001]
  • [Cites] J Natl Cancer Inst. 1981 Jun;66(6):1037-52 [6941039.001]
  • [Cites] Nature. 1983 Jul 21-27;304(5923):219-26 [6346107.001]
  • [Cites] Science. 1985 May 10;228(4700):669-77 [3992240.001]
  • [Cites] Science. 1987 Jan 16;235(4786):305-11 [3541204.001]
  • [Cites] Science. 1987 Mar 13;235(4794):1394-9 [3823889.001]
  • [Cites] J Theor Biol. 1987 Aug 21;127(4):381-91 [3328018.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):4923-7 [1594595.001]
  • [Cites] Blood. 1993 Mar 15;81(6):1573-9 [8453103.001]
  • [Cites] Epidemiology. 1993 May;4(3):204-17 [8512985.001]
  • [Cites] J R Soc Interface. 2008 Jan 6;5(18):105-21 [17580291.001]
  • [Cites] Oncogene. 2008 Apr 24;27(19):2754-62 [17998936.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6215-21 [18434545.001]
  • [Cites] J Theor Biol. 2008 May 21;252(2):295-312 [18371982.001]
  • [Cites] J Theor Biol. 2008 Sep 21;254(2):229-38 [18640693.001]
  • [Cites] Cell Prolif. 2008 Dec;41(6):980-7 [19040573.001]
  • [Cites] J Math Biol. 2009 Apr;58(4-5):765-98 [18781303.001]
  • [Cites] Trends Mol Med. 2009 Jan;15(1):5-13 [19091631.001]
  • [Cites] EMBO J. 1995 Sep 1;14(17):4240-8 [7556065.001]
  • [Cites] Biometrics. 1995 Dec;51(4):1278-91 [8589222.001]
  • [Cites] Stat Med. 1996 May 30;15(10):1003-22 [8783438.001]
  • [Cites] Radiat Environ Biophys. 1996 May;35(2):127-9 [8792461.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14800-3 [8962135.001]
  • [Cites] Risk Anal. 1996 Oct;16(5):711-5 [8962520.001]
  • [Cites] Nature. 1997 Apr 10;386(6625):623-7 [9121588.001]
  • [Cites] Nature. 1997 Apr 24;386(6627):761, 763 [9126728.001]
  • [Cites] Int J Cancer. 1997 Jul 17;72(2):205-9 [9219821.001]
  • [Cites] Risk Anal. 1997 Jun;17(3):391-9 [9232020.001]
  • [Cites] Radiat Res. 1997 Oct;148(4):348-58 [9339951.001]
  • [Cites] Br J Cancer. 1998;77(2):243-52 [9460995.001]
  • [Cites] Anticancer Res. 1990 Mar-Apr;10(2B):475-87 [2190526.001]
  • [Cites] Anticancer Res. 1990 Mar-Apr;10(2B):497-504 [2350160.001]
  • [Cites] Cancer Res. 1991 Jun 15;51(12):3075-9 [2039987.001]
  • [Cites] J Natl Cancer Inst. 1992 Apr 15;84(8):610-8 [1313509.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3385-8 [1565631.001]
  • [Cites] EMBO J. 1992 May;11(5):1921-9 [1582420.001]
  • [Cites] Cancer Cell. 2007 Oct;12(4):313-27 [17936557.001]
  • [Cites] Lancet Oncol. 2007 Nov;8(11):1030-8 [17976613.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):469-76 [10688867.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1254-60 [10728684.001]
  • [Cites] Mol Pathol. 2000 Aug;53(4):184-7 [11040940.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6510-8 [11103821.001]
  • [Cites] Nat Genet. 2000 Dec;26(4):447-50 [11101843.001]
  • [Cites] Radiat Environ Biophys. 2000 Dec;39(4):253-64 [11200969.001]
  • [Cites] Nat Cell Biol. 2001 Apr;3(4):433-8 [11283620.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1517-24 [11290569.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3230-9 [11309271.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 8;98(10):5379-81 [11344279.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 8;98(10):5770-5 [11296254.001]
  • [Cites] Math Biosci. 2001 Jun;171(2):113-42 [11395047.001]
  • [Cites] Hum Mutat. 2007 Dec;28(12):1207-15 [17688236.001]
  • [Cites] Biochemistry (Mosc). 1997 Nov;62(11):1180-90 [9467840.001]
  • [Cites] Nature. 1998 Mar 19;392(6673):300-3 [9521327.001]
  • [Cites] Cancer. 1998 May 15;82(10):1808-20 [9587112.001]
  • [Cites] Nature. 1998 Dec 17;396(6712):643-9 [9872311.001]
  • [Cites] Nat Med. 1999 Jan;5(1):11-2 [9883827.001]
  • [Cites] Radiat Res. 1999 Feb;151(2):209-17 [9952306.001]
  • [Cites] Curr Opin Cell Biol. 1999 Jun;11(3):318-24 [10395557.001]
  • [Cites] J Exp Med. 1999 Jul 19;190(2):153-6 [10432278.001]
  • [Cites] Radiat Res. 1999 Oct;152(4):339-51 [10477911.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):683-94 [10487825.001]
  • [Cites] Science. 1963 May 3;140(3566):490-2 [13980636.001]
  • [Cites] Exp Cell Res. 1965 Mar;37:614-36 [14315085.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):298-306 [15549091.001]
  • [Cites] Semin Cancer Biol. 2005 Feb;15(1):51-60 [15613288.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):17-23 [15652746.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1071-5 [15657129.001]
  • [Cites] Bioessays. 2005 Aug;27(8):833-8 [16015588.001]
  • [Cites] Semin Cancer Biol. 2005 Dec;15(6):436-50 [16055343.001]
  • [Cites] Trends Genet. 2006 Jan;22(1):46-55 [16257470.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1858-63 [16443684.001]
  • [Cites] Theor Biol Med Model. 2006;3:7 [16472396.001]
  • [Cites] Ann ICRP. 2005;35(4):1-140 [16782497.001]
  • [Cites] Int J Epidemiol. 2006 Oct;35(5):1151-9 [16987840.001]
  • [Cites] Int J Epidemiol. 2006 Oct;35(5):1165-7 [16990285.001]
  • [Cites] J Pathol. 2007 Jan;211(2):114-23 [17200948.001]
  • [Cites] Carcinogenesis. 2007 Feb;28(2):479-87 [16973671.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Aug;19(6):370-84 [17399964.001]
  • [Cites] Leukemia. 2007 Sep;21(9):2061-4 [17495966.001]
  • [Cites] Br J Cancer. 2007 Sep 3;97(5):646-53 [17687336.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15121-6 [10611348.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Math Med Biol. 2009 Mar;26(1):63-95 [19033598.001]
  • [Cites] Br J Cancer. 2009 Jun 16;100(12):1917-25 [19455139.001]
  • [Cites] J Mol Model. 2009 Dec;15(12):1517-39 [19466466.001]
  • [Cites] PLoS One. 2009;4(12):e8520 [20046831.001]
  • [Cites] PLoS One. 2010;5(1):e8915 [20111720.001]
  • [Cites] Biol Direct. 2010;5:22 [20406440.001]
  • [Cites] Biol Direct. 2010;5:26 [20406446.001]
  • [Cites] Risk Anal. 1988 Sep;8(3):383-92 [3201016.001]
  • [Cites] Science. 1989 Nov 3;246(4930):629-34 [2683079.001]
  • [Cites] Radiat Res. 1990 Jan;121(1):28-37 [2153988.001]
  • [Cites] Am J Physiol. 1990 Apr;258(4 Pt 1):E727-36 [2333964.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 15;93(16):1215-23 [11504767.001]
  • [Cites] Radiat Res. 2001 Nov;156(5 Pt 2):618-27 [11604083.001]
  • [Cites] Radiat Res. 2001 Nov;156(5 Pt 2):672-7 [11604091.001]
  • [Cites] Int J Radiat Biol. 2002 Jan;78(1):49-68 [11747553.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):46-54 [11900251.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 May;282(5):C947-70 [11940508.001]
  • [Cites] J Natl Cancer Inst. 2002 Jun 19;94(12):883-93 [12072542.001]
  • [Cites] Hum Genet. 2002 Sep;111(3):284-9 [12215842.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15095-100 [12415112.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16226-31 [12446840.001]
  • [Cites] Math Biosci. 2003 Jun;183(2):111-34 [12711407.001]
  • [Cites] Radiat Res. 2003 May;159(5):567-80 [12710868.001]
  • [Cites] Radiat Res. 2003 May;159(5):581-96 [12710869.001]
  • [Cites] Radiat Res. 2003 May;159(5):656-62 [12710877.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):401-10 [12778130.001]
  • [Cites] Cell Prolif. 2003 Jun;36(3):115-29 [12814429.001]
  • [Cites] DNA Cell Biol. 2003 Apr;22(4):225-6 [12823898.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2920-5 [12912937.001]
  • [Cites] Int J Cancer. 2003 Dec 10;107(5):688-95 [14566816.001]
  • (PMID = 20406436.001).
  • [ISSN] 1745-6150
  • [Journal-full-title] Biology direct
  • [ISO-abbreviation] Biol. Direct
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 166
  • [Other-IDs] NLM/ PMC2873266
  •  go-up   go-down


50. Krengli M, Milia ME, Turri L, Mones E, Bassi MC, Cannillo B, Deantonio L, Sacchetti G, Brambilla M, Inglese E: FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of anal carcinoma. Radiat Oncol; 2010;5:10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of anal carcinoma.
  • BACKGROUND: FDG-PET/CT imaging has an emerging role in staging and treatment planning of various tumor locations and a number of literature studies show that also the carcinoma of the anal canal may benefit from this diagnostic approach.
  • We analyzed the potential impact of FDG-PET/CT in stage definition and target volume delineation of patients affected by carcinoma of the anal canal and candidates for curative radiotherapy.
  • METHODS: Twenty seven patients with biopsy proven anal carcinoma were enrolled.
  • Pathology was squamous cell carcinoma in 20 cases, cloacogenic carcinoma in 3, adenocarcinoma in 2, and basal cell carcinoma in 2.
  • RESULTS: PET/CT fused images led to change the stage in 5/27 cases (18.5%): 3 cases from N0 to N2 and 2 from M0 to M1 leading to change the treatment intent from curative to palliative in a case.Based on PET/CT imaging, GTV and CTV contours changed in 15/27 (55.6%) and in 10/27 cases (37.0%) respectively.
  • CONCLUSIONS: FDG-PET/CT has a potential relevant impact in staging and target volume delineation of the carcinoma of the anal canal.
  • Clinical stage variation occurred in 18.5% of cases with change of treatment intent in 3.7%.
  • [MeSH-major] Anus Neoplasms / pathology. Carcinoma / pathology. Neoplasm Staging / methods. Radiotherapy Planning, Computer-Assisted / methods. Radiotherapy, Conformal

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 2001 Oct;61(1):15-22 [11578724.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):824-30 [19117696.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):893-900 [15936575.001]
  • [Cites] Mol Imaging Biol. 2005 Jul-Aug;7(4):309-13 [16028002.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):720-5 [16626889.001]
  • [Cites] Technol Cancer Res Treat. 2007 Feb;6(1):31-6 [17241098.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):155-62 [17707268.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Apr 1;70(5):1423-6 [17931795.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):180-6 [17996387.001]
  • [Cites] Med Phys. 2008 Apr;35(4):1207-13 [18491512.001]
  • [Cites] Radiother Oncol. 2008 Jun;87(3):376-82 [18453023.001]
  • [Cites] Br J Cancer. 2009 Mar 10;100(5):693-700 [19259091.001]
  • [Cites] Strahlenther Onkol. 2009 Apr;185(4):254-9 [19370429.001]
  • [Cites] Br J Radiol. 2009 Jun;82(978):509-13 [19153180.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]
  • (PMID = 20137093.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC2851594
  •  go-up   go-down


51. Jung M, Ramankulov A, Roigas J, Johannsen M, Ringsdorf M, Kristiansen G, Jung K: In search of suitable reference genes for gene expression studies of human renal cell carcinoma by real-time PCR. BMC Mol Biol; 2007;8:47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In search of suitable reference genes for gene expression studies of human renal cell carcinoma by real-time PCR.
  • No conclusive systematic study comparing the suitability of different candidate reference genes in clear cell renal cell carcinoma has been published to date.
  • RESULTS: The expression of the potential reference genes was examined in matched malignant and non-malignant tissue specimens from 25 patients with clear cell renal cell carcinoma.
  • The expression of all genes did not depend on age, sex, and tumour stage.
  • CONCLUSION: Our study demonstrated the suitability of the two housekeeping genes PPIA and TBP as endogenous reference genes when comparing malignant tissue samples with adjacent normal tissue samples from clear cell renal cell carcinoma.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Gene Expression Regulation, Neoplastic / genetics. Genes, Neoplasm / genetics. Kidney Neoplasms / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Biochem. 2002 Oct 15;309(2):293-300 [12413463.001]
  • [Cites] Thorax. 2002 Sep;57(9):765-70 [12200519.001]
  • [Cites] Yakugaku Zasshi. 2003 May;123(5):369-75 [12772594.001]
  • [Cites] Kidney Int. 2003 Jul;64(1):356-60 [12787429.001]
  • [Cites] Nat Genet. 2003 Dec;35(4):292-3 [14647279.001]
  • [Cites] Kidney Int. 2004 Jan;65(1):97-105 [14675040.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 23;313(4):856-62 [14706621.001]
  • [Cites] Anal Biochem. 2004 May 15;328(2):101-8 [15113684.001]
  • [Cites] Biotechnol Lett. 2004 Mar;26(6):509-15 [15127793.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5245-50 [15289330.001]
  • [Cites] Genome Biol. 2004;5(8):R59 [15287981.001]
  • [Cites] J Biomol Tech. 2004 Sep;15(3):155-66 [15331581.001]
  • [Cites] J Urol (Paris). 1994;100(4):189-95 [7868931.001]
  • [Cites] Anal Biochem. 2004 Dec 1;335(1):1-9 [15519565.001]
  • [Cites] Mol Diagn. 2004;8(2):107-13 [15527325.001]
  • [Cites] Kidney Int. 2004 Dec;66(6):2308-14 [15569320.001]
  • [Cites] Lab Invest. 2005 Jan;85(1):154-9 [15543203.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):1043-52 [15592504.001]
  • [Cites] Nucleic Acids Res. 2005;33(6):e56 [15800207.001]
  • [Cites] Genes Immun. 2005 Jun;6(4):279-84 [15815687.001]
  • [Cites] J Mol Endocrinol. 2005 Jun;34(3):597-601 [15956331.001]
  • [Cites] Anal Biochem. 2005 Sep 1;344(1):141-3 [16054107.001]
  • [Cites] Biomarkers. 2005 Jul-Aug;10(4):258-94 [16191485.001]
  • [Cites] J Mol Med (Berl). 2005 Dec;83(12):1014-24 [16211407.001]
  • [Cites] BMC Mol Biol. 2006;7:3 [16448564.001]
  • [Cites] J Urol. 2006 May;175(5):1915-20 [16600798.001]
  • [Cites] Eur Urol. 2006 May;49(5):798-805 [16442207.001]
  • [Cites] Int J Urol. 2006 Mar;13(3):265-70 [16643621.001]
  • [Cites] Mar Biotechnol (NY). 2006 Jul-Aug;8(4):398-408 [16676145.001]
  • [Cites] Anal Biochem. 2006 Sep 1;356(1):36-43 [16844072.001]
  • [Cites] BMC Mol Biol. 2006;7:33 [17026756.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] J Biotechnol. 1999 Oct 8;75(2-3):291-5 [10617337.001]
  • [Cites] J Mol Endocrinol. 2000 Oct;25(2):169-93 [11013345.001]
  • [Cites] J Biochem Biophys Methods. 2000 Nov 20;46(1-2):69-81 [11086195.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 3;94(7):513-21 [11929952.001]
  • [Cites] Anal Biochem. 2002 Apr 15;303(2):209-14 [11950223.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] J Mol Endocrinol. 2002 Aug;29(1):23-39 [12200227.001]
  • [Cites] Physiol Genomics. 2003 Jan 15;12(2):163-74 [12419855.001]
  • (PMID = 17559644.001).
  • [ISSN] 1471-2199
  • [Journal-full-title] BMC molecular biology
  • [ISO-abbreviation] BMC Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Proteins; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / ADAM9 protein, human
  • [Other-IDs] NLM/ PMC1913536
  •  go-up   go-down


52. Hazard LJ, Shrieve DC, Sklow B, Pappas L, Boucher KM: Local Excision vs. Radical Resection in T1-2 Rectal Carcinoma: Results of a Study From the Surveillance, Epidemiology, and End Results (SEER) Registry Data. Gastrointest Cancer Res; 2009 May;3(3):105-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local Excision vs. Radical Resection in T1-2 Rectal Carcinoma: Results of a Study From the Surveillance, Epidemiology, and End Results (SEER) Registry Data.
  • BACKGROUND: Local excision (LE) has been used in an attempt to preserve anal function in T1-2 rectal carcinoma.
  • METHODS: Patients reported to the SEER registry of the National Cancer Institute from 1988 to 2003 who had T1-2N0M0 rectal carcinoma were identified.
  • Randomized trials are necessary to determine if LE with or without RT can offer equivalent survival compared to RR in early stage rectal carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2007 Oct;50(10):1520-5 [17674104.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):313-22 [10661337.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):472-8 [17498568.001]
  • [Cites] Ann Surg. 2007 May;245(5):726-33 [17457165.001]
  • [Cites] J Clin Oncol. 2007 Apr 1;25(10):1255-9 [17401014.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):912-7 [17325705.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):110-7 [17194912.001]
  • [Cites] Hepatogastroenterology. 2005 Nov-Dec;52(66):1688-91 [16334758.001]
  • [Cites] Br J Surg. 2005 Dec;92(12):1546-52 [16252312.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8697-705 [16314629.001]
  • [Cites] Ann Surg. 2005 Oct;242(4):472-7; discussion 477-9 [16192807.001]
  • [Cites] Dis Colon Rectum. 2005 Jul;48(7):1380-8 [15906120.001]
  • [Cites] Dis Colon Rectum. 2004 Nov;47(11):1773-9 [15622568.001]
  • [Cites] Ann Surg Oncol. 1999 Jul-Aug;6(5):433-41 [10458680.001]
  • [Cites] Arch Surg. 1999 Aug;134(8):863-7; discussion 867-8 [10443810.001]
  • [Cites] Ann Surg. 1999 Jul;230(1):49-54 [10400036.001]
  • [Cites] Dis Colon Rectum. 1996 Oct;39(10 Suppl):S79-84 [8831552.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2716-20 [8194011.001]
  • [Cites] Dis Colon Rectum. 1994 Dec;37(12):1189-93 [7995142.001]
  • [Cites] N Engl J Med. 1992 Mar 5;326(10):658-62 [1736104.001]
  • [Cites] Cancer. 1992 Jan 15;69(2):322-6 [1728363.001]
  • [Cites] N Engl J Med. 1991 Mar 14;324(11):709-15 [1997835.001]
  • [Cites] Br J Urol. 1981 Dec;53(6):558-64 [7317742.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] Surg Endosc. 2003 Aug;17(8):1283-7 [12739119.001]
  • [Cites] Ann Surg. 2003 Aug;238(2):203-13 [12894013.001]
  • [Cites] Dis Colon Rectum. 2002 Sep;45(9):1178-85 [12352233.001]
  • [Cites] Am Surg. 2001 Aug;67(8):774-9 [11510582.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Ann Surg. 2001 Feb;233(2):149-56 [11176118.001]
  • [Cites] Dis Colon Rectum. 2000 Oct;43(10 Suppl):S59-68 [11052480.001]
  • [Cites] Dis Colon Rectum. 2000 Aug;43(8):1064-71; discussion 1071-4 [10950004.001]
  • [Cites] Am J Surg. 2000 Apr;179(4):271-4 [10875984.001]
  • [Cites] Int J Colorectal Dis. 2007 Nov;22(11):1325-30 [17571241.001]
  • (PMID = 19626153.001).
  • [ISSN] 1934-7820
  • [Journal-full-title] Gastrointestinal cancer research : GCR
  • [ISO-abbreviation] Gastrointest Cancer Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2713135
  •  go-up   go-down


53. Zakharash MP, Poĭda AI, Mel'nik VM: [Abdomino-anal resection in the treatment of low-ampullar cancer of the rectum]. Khirurgiia (Mosk); 2005;(4):52-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Abdomino-anal resection in the treatment of low-ampullar cancer of the rectum].
  • Surgical policy was developed for improvement of functional results and quality of life in patients operated on for low rectal cancer.
  • This policy includes choice of the method of sphincter-saving operation depending on the stage of the tumor, grade of malignancy, distance from a low edge of the tumor to dentate line.
  • Methods of prevention of ischemia and necrosis of brought down colonic transplant and anal incontinence were used.
  • This increased the number of sphincter-saving operations in low location of rectal cancer by 35%, reduced the rate of necrosis of intestinal transplant from 7 to 4.4%, saved continent function and improved significantly quality of life in 89.8% operated patients.
  • [MeSH-major] Anal Canal / surgery. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15940181.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


54. Erren TC, Glende CB, Morfeld P, Piekarski C: Is exposure to silica associated with lung cancer in the absence of silicosis? A meta-analytical approach to an important public health question. Int Arch Occup Environ Health; 2009 Aug;82(8):997-1004
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is exposure to silica associated with lung cancer in the absence of silicosis? A meta-analytical approach to an important public health question.
  • OBJECTIVE: This report investigates epidemiologically whether exposure to silica is associated with lung cancer risks in individuals without silicosis.
  • METHODS: We searched the PubMed reference data base from 1966 through 1/2007 for reports of lung cancer in silica-exposed persons without and with silicosis.
  • To explore heterogeneity between studies, a multi-stage strategy was employed.
  • RESULTS: The persistence of a significant link between silicosis and lung cancer since the characterisation in 1997 of silica as a human carcinogen [our estimates of lung cancer relative risks (RR) exceeded unity in each of 38 eligible studies of silicotics published until 1/2007, averaging 2.1 in analyses based on both fixed and random effect models (95% CI = (2.0-2.3) and (1.9-2.3), respectively)] does not resolve our study question, namely whether exposure to silica levels below those required to induce silicosis are carcinogenic.
  • Importantly, our detailed examination of 11 studies of lung cancer in silica-exposed individuals without silicosis included only three with data allowing adjustment for smoking habits.
  • They yielded a pooled RR estimate of 1.0 [95% CI = (0.8-1.3)].
  • The other eight studies, with no adjustment for smoking habits, suggested a marginally elevated risk of lung cancer [RR = 1.2; 95% CI (1.1-1.4)], but with significant heterogeneity between studies (P approximately 0.05).
  • Time-dependent information on silicosis and on silica dust is required as well as the application of methods like G-estimation to answer the important public health question: Is silicosis a necessary condition for the elevation of silica-associated lung cancer risks?